titanium dioxide coated to reduce the bleaching effect on the skin

专利摘要:
COATED TITANIUM DIOXIDE TO REDUCE THE WHITENING EFFECT ON THE SKIN. The present invention relates to coated titanium dioxide particles, wherein at least one coating layer comprises an ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids as the coating material.
公开号:BR102015005868B1
申请号:R102015005868-3
申请日:2015-03-17
公开日:2021-01-26
发明作者:William Johncock；Simone Peters；Martina Issleib；Jürgen Claus
申请人:Symrise Ag；
IPC主号:

专利说明:

[0001] [001] The present invention belongs to the field of cosmetic and pharmaceutical preparations, especially dermatological preparations and refers to the protection of human skin and human hair against the harmful effects of ultraviolet (UV) radiation. The cosmetic and pharmaceutical preparations of the present invention comprise a specially coated titanium dioxide which reduces the residual bleaching effect, in particular on the skin after application and improves the skin feel of the finished formulation. TECHNICAL STATUS
[0002] [002] UV absorbers are compounds that have a pronounced absorption capacity for ultraviolet radiation. They are used in particular as sunscreens in cosmetic, dermatological and pharmacological preparations, but also to improve light stability of industrial products, such as paints, varnishes, plastics, textiles, polymers such as, for example, mono polymers and copolymers - and diolefins, polystyrenes, polyurethanes, polyamides, polyesters, polyureas and polycarbonates, packaging materials and rubbers.
[0003] [003] UV rays are classified according to the wavelength as UVA rays (320 to 400 nm, UVA-I: 340 to 400 nm, UVA-II: 320 to 340 nm) or UVB rays (280 to 320 nm). UV rays can cause acute and chronic skin damage, the type of damage depending on the wavelength of the radiation. For example, UVB radiation can cause sunburn (erythema) that extend to the most severe skin burn; reduction of enzyme activities, weakening of the immune system, disorders of DNA structure and changes in the cell membrane are also known as harmful effects of UVB rays. UVA rays penetrate the deeper layers of the skin, where they can accelerate the skin's aging process. The shorter wave UVA-II radiation additionally contributes to the development of sunburn. In addition, UVA radiation can activate phototoxic or photoallergic skin reactions. The very frequent and unprotected irradiation of the skin by sunlight leads to a loss of skin elasticity and the increased development of wrinkles. In extreme cases, pathogenic changes in the skin that extend to skin cancer are observed. To mitigate these negative effects of UV radiation, materials that absorb or reflect UV light, generally called UV absorbers, are used in cosmetic, dermatological and pharmacological preparations. UV absorbers are classified as UVA and UVB absorbers, depending on the location of their absorption maximums; if a UV absorber absorbs both UVA and UVB, it is referred to as a wide-range UVA / B absorber.
[0004] [004] The UV absorbers typically used are classified as organic, based on carbon, hydrogen and oxygen atoms or inorganic pigments based on titanium dioxide or zinc oxide.
[0005] [005] Titanium dioxide has been used for decades as a white pigment for paints and make-up due to its very high refractive index which makes it one of the whitest known pigments, with a refractive index of around 2.6. Since most cosmetic, dermatological and pharmacological preparations for the protection of human skin have a refractive index of around 1.5, it is very difficult to hide the whiteness of titanium dioxide when it is incorporated in such a preparation (Fairhurst & Mitchnick: of Sunscreens Development, Evaluation and Regulatory Aspects, 2nd Edition, edited by Shaath et.al. Cosmetic Science & Technology Series / Volume 15 Chapter 17, Page 320, 1997, Marcel Dekker Inc).
[0006] [006] The dispersion of radiation through the pigmentary particles is not only dependent on the refractive index, but also on its particle size, and the maximum visible radiation dispersion for titanium dioxide is around 220 nm (see Fairhurst reference, page 322).
[0007] [007] Since titanium dioxide is also a semiconductor with a range of 3.05 eV (= 405 nm), UV radiation with wavelengths less than 405 nm will be absorbed by it. It is this absorption that makes titanium dioxide a candidate for use in UV protection products. However, the desirable bleaching effect of pigment grades of titanium dioxide with particle sizes greater than 200 nm for its application in decorative paints and cosmetics is an undesirable effect in cosmetic, dermatological and pharmacological preparations for skin protection against the harmful effects of UV radiation, since the residual whitening left on the skin is considered to be unattractive. Thus, in the last two decades of the 20th century, categories of titanium dioxide were developed, which had a much smaller particle size (20 to 80 nm) to reduce the bleaching effect caused by the reflection, while at the same time, significantly improves the substance's ability to reflect UV radiation in the UVB range. However, the pure categories of titanium nano dioxide have two main properties that had to be overcome before they could be incorporated into cosmetic, dermatological and pharmacological preparations to protect human skin from the harmful effects of UV radiation. First, since titanium dioxide absorbs UV radiation, it is an efficient photocatalyst that causes the release of free radicals involved in oxidative processes that are undesirable in cosmetic, dermatological and pharmacological preparations for the protection of human skin. Second, once incorporated into an emulsion, solid pigment particles of titanium dioxide tend to clump together into larger particles and as soon as these particles reach a size of 220 to 250 nm, they again become efficient in reflecting light White.
[0008] [008] These two properties have been overcome to some extent, especially with regard to reducing photoreactivity, by efficiently coating individual titanium dioxide particles with various coatings, for example, silica (SiO2), hydroxide aluminum (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate (Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, as the only components or as mixtures.
[0009] [009] As a result, the use of nano titanium dioxide categories has become an ingredient commonly used in cosmetic, dermatological and pharmacological preparations for the protection of human skin against the harmful effects of UV radiation. However, the residual bleaching effect of these titanium dioxide qualities in cosmetic, dermatological and pharmacological preparations for the protection of human skin against the harmful effects of UV radiation is still unacceptable. In addition, the incorporation of titanium nano dioxide in such preparations also leaves the skin with an unacceptable feeling, as it is not smooth, but dull and rough, which then requires the addition of other cosmetic ingredients such as waxes and oils for its attenuation, increasing the complexity and cost of manufacturing the preparations.
[0010] [0010] It has also been discovered that if titanium dioxide particles are coated with aluminum salts or oxides and then formulated in cosmetic and pharmaceutical preparations, especially dermatological ones to protect human skin from the harmful effects of UV radiation containing the UVA filter widely used Avobenzone, there is an undesirable reaction between aluminum ions and Avobenzone that results in the formation of insoluble aluminum complexes of Avobenzone that crystallize out of the formulation, thus reducing its effectiveness and aesthetics as described in US 2012/0294916 A1.
[0011] [0011] The purpose of the present invention is thus to provide titanium dioxide in cosmetic and pharmaceutical preparations, especially in dermatological preparations, to protect human skin against the harmful effects of UV radiation, without the above mentioned disadvantages. DESCRIPTION OF THE INVENTION
[0012] [0012] Surprisingly, it has been observed that by coating titanium dioxide with a wax comprising an ester produced from a mixture of fatty alcohols and C6 to C12 aliphatic acids, the residual bleaching effects are noticeably greatly reduced. Furthermore, it has been observed that cosmetic and pharmaceutical preparations for the protection of human skin against the harmful effects of UV radiation, preferably the respective dermatological preparations comprising titanium dioxide coated with wax, which comprises an ester produced from a mixture of fatty alcohol and aliphatic acids C6 to C12, have a smoother skin sensation than preparations with titanium dioxide, which is not coated with the respective wax.
[0013] [0013] Therefore, the present invention relates to the coated titanium dioxide particles, wherein at least one coating layer comprises an ester produced from the mixture of fatty alcohol and C6 to C12 aliphatic acids as the coating material.
[0014] [0014] "Coating material" in the sense of the invention is a substance or a mixture of various substances that is used to coat particles.
[0015] [0015] Regarding the mixture of fatty alcohol and C6 to C12 aliphatic acids, which results in a fatty ester, all combinations of fatty alcohol and C6 to C12 aliphatic acids are possible. Preferably, the resulting fatty esters are derived from C12 to C30 fatty alcohols esterified with C6 to C12 acids. More preferably, the fatty esters are derived from C14 to C20 fatty alcohols and most preferably from C16 to C18 alcohols esterified with C8 to C10 acids.
[0016] [0016] Preferably, the wax, respectively the ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids, as the coating material, is a derivative of C16 to C18 nonanoate or a mixture thereof. Thus, in a preferred embodiment, the at least one coating layer comprises cetearyl nonoate and / or cetearyl isononoate as the coating material.
[0017] [0017] The most preferable are the coated titanium dioxide particles, in which at least one coating layer comprises cetearyl nonanoate (SymMollient® S sold by Symrise AG) as a coating material.
[0018] [0018] In addition, surprisingly, by coating titanium dioxide with an ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids, as a coating material, preferably a derivative of C16 - C18 nonanoate or a mixture of this, more preferably cetearyl nonoate and / or cetearyl isononoate, no interaction with Avobenzone, which is a common UV filter, was observed when another coating layer was used to coat the titanium dioxide particles.
[0019] [0019] Therefore, another preferred embodiment of the present invention is the titanium dioxide particles coated according to the invention, wherein the titanium dioxide particles comprise one or more additional coating layers, whereby the additional coating material is selected from the group consisting of silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate (Na (PO3) 6), sodium metaphosphate (Na (PO3) n , aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof.
[0020] [0020] The coating layers comprising wax as the coating material and additional coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate ( Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof, is variable in the order of the coating layer. This means that titanium oxide particles can be coated first with wax and later with additional coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina , sodium hexametaphosphate (Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof, or vice versa.
[0021] (i) pelo menos uma primeira camada de revestimento compreende um material de revestimento selecionado de sílica (SiO2), hidróxido de alumínio (Al2(OH)3, óxido de alumínio (Al2O3), alumina, hexametafosfato de sódio (Na(PO3)6), metafosfato de sódio (Na(PO3)n, estearato de alumínio, ácido esteárico, ácido láurico, dimetilpolissiloxano, dimeticona, metilpolissiloxano, simeticona, ou suas misturas, e (ii) pelo menos uma segunda camada de revestimento (externa), em que o material de revestimento compreende um éster produzido a partir de uma mistura de álcool graxo e ácidos alifáticos C6 a C12, como o material de revestimento, preferivelmente um derivado de nonanoato C16 a C18 ou uma mistura destes, mais preferivelmente nonoato de cetearila e / ou isononoato de cetearila. [0021] Therefore, a preferred embodiment is the titanium dioxide particles coated according to the invention, which comprise (i) at least one first coating layer comprises a coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate (Na (PO3) 6 ), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof, and mixtures thereof, and (ii) at least a second coating layer (outer), wherein the coating material comprises an ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids, as the coating material, preferably a nonanoate derivative C16 to C18 or a mixture thereof, more preferably cetearyl nonoate and / or cetearyl isononoate.
[0022] (i) pelo menos uma primeira camada de revestimento compreende um material de revestimento selecionado de sílica (SiO2), hidróxido de alumínio (Al2(OH)3, óxido de alumínio (Al2O3), alumina, hexametafosfato de sódio (Na(PO3)6), metafosfato de sódio (Na(PO3)n, estearato de alumínio, ácido esteárico, ácido láurico, dimetilpolissiloxano, dimeticona, metilpolissiloxano, simeticona, ou suas misturas, e (ii) pelo menos uma segunda camada de revestimento (externa), em que o material de revestimento compreende nonanoato de cetearila (SimMollient® S vendido por Simrise AG). [0022] The most preferable are the coated titanium dioxide particles which comprise (i) at least one first coating layer comprises a coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate (Na (PO3) 6 ), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof, and mixtures thereof, and (ii) at least a second (external) coating layer, wherein the coating material comprises cetearyl nonanoate (SimMollient® S sold by Simrise AG).
[0023] (i) pelo menos uma primeira camada de revestimento, em que o material de revestimento compreende um éster produzido a partir de uma mistura de álcool graxo e ácidos alifáticos C6 a C12, como o material de revestimento, preferivelmente um derivado de nonanoato C16 a C18 ou uma mistura destes, mais preferivelmente nonoato de cetearila e / ou isononoato de cetearila, e (ii) pelo menos uma segunda camada de revestimento (externa), que compreende um material de revestimento selecionado de sílica (SiO2), hidróxido de alumínio (Al2(OH)3, óxido de alumínio (Al2O3), alumina, hexametafosfato de sódio (Na(PO3)6), metafosfato de sódio (Na(PO3)n, estearato de alumínio, ácido esteárico, ácido láurico, dimetilpolissiloxano, dimeticona, metilpolissiloxano, simeticona, ou suas misturas. [0023] Optionally, the titanium dioxide particles coated according to the invention, comprise (i) at least one first coating layer, wherein the coating material comprises an ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids, as the coating material, preferably a derivative of C16 to C18 nonanoate or a mixture of these, more preferably cetearyl nonoate and / or cetearyl isononoate, and (ii) at least a second (external) coating layer, comprising a coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate ( Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof.
[0024] (i) pelo menos uma primeira camada de revestimento, em que o material de revestimento compreende nonanoato de cetearila (SimMollient® S vendido por Simrise AG), e (ii) pelo menos uma segunda camada de revestimento (externa), que compreende um material de revestimento selecionado de sílica (SiO2), hidróxido de alumínio (Al2(OH)3, óxido de alumínio (Al2O3), alumina, hexametafosfato de sódio (Na(PO3)6), metafosfato de sódio (Na(PO3)n, estearato de alumínio, ácido esteárico, ácido láurico, dimetilpolissiloxano, dimeticona, metilpolissiloxano, simeticona, ou suas misturas. [0024] In this case, the most preferable are the coated titanium dioxide particles which comprise (i) at least one first coating layer, wherein the coating material comprises cetearyl nonanoate (SimMollient® S sold by Simrise AG), and (ii) at least a second (external) coating layer, comprising a coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate ( Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof.
[0025] [0025] The coated titanium dioxide particles of the present invention may have more than two layers of coating of the aforementioned coating materials. Thus, the alternating coating layers of the mentioned coating material can be applied over a titanium oxide particle. A titanium oxide particle of the present invention can have up to 4 layers of coating.
[0026] [0026] In another embodiment, the coated titanium dioxide particles of the present invention have a wax loading capacity, which comprises an ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids, as the coating material , preferably a derivative of C16 to C18 nonanoate or a mixture thereof, more preferably cetearyl nonoate and / or cetearyl isononoate, most preferable cetearyl nonanoate (SymMollient® S sold by Symrise AG), in the range of 5 to 25% in weight, referring to the total weight of a particle. Preferably, the load capacity is in the range of 10 to 25% by weight, more preferably in the range of 10 to 15% by weight, referring to the total weight of a particle.
[0027] [0027] In another embodiment, the titanium dioxide coated particles of the present invention have a loading capacity for the additional coating material selected from silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3) , alumina, sodium hexametaphosphate (Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof, in the range of 5 to 15% by weight, more preferably in the range of 5 to 10% by weight, referring to the total weight of a particle.
[0028] [0028] The titanium dioxide particles coated according to the invention have an average particle size in which at least one dimension of the individual crystals constituting the particle clusters is <100 nm.
[0029] [0029] The coated titanium dioxide particles of the invention are used in cosmetic and pharmaceutical preparations, especially in dermatological preparations. Thus, another object of the present invention is cosmetic or pharmaceutical preparations comprising particles of titanium dioxide coated as described above.
[0030] [0030] Especially, a preferred embodiment of the present invention are cosmetic or pharmaceutical preparations, especially dermatological preparations, which comprise the titanium dioxide particles coated according to the invention described above, in the reference range for the total preparation.
[0031] [0031] The amount of titanium dioxide particles coated according to the invention in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, is in the range of 0.1 to 35% by weight, preferably 0.3 to 30 % by weight, more preferably from 0.5 to 25% by weight of the total formulation. UV FILTERS
[0032] [0032] Another objective of the present invention is cosmetic or pharmaceutical preparations, especially dermatological preparations, comprising the coated titanium dioxide particles of the invention and at least one additional UV filter in an amount of 0.1 to 65.0% by weight, preferably in the range of 2 to 50% by weight and most preferably in the range of 5 to 35% by weight, preferably referring to the total amount of all UV filters, with reference to the total amount of the preparation.
[0033] • Avobenzona • Homossalato • Octissalato • Octocrileno • 2-Etilexil p-metoxicinamato • Isoamil p-metoxicinamato • 3-(4'-metilbenzilideno)-d,l-cânfora • 2,4,6-trianilino(p-carbo-2'-etilexil-1'-óxi)-1,3,5-triazina • Tris-Bifenil Triazina • Dietilexil Butamido Triazona • Benzilidenomalonato-polissiloxano • 4-dimetilaminobenzoato de 2-etilexila • Trissiloxano de Drometrizol • Bis-Etilexiloxifenol Metoxifenil Triazina • 2,2’-Metilenobis(6-(2H-benztriazol-2-il)-4-1,1,3,3-tetrametilbutil)- fenol), • Benzoato de Dietilamino Hidroxibenzoil Hexila • Tetrassulfonato de Fenil-dibenzimidazol Dissódico e seus sais • Ácido fenilbenzimidazol-sulfônico e seus sais • Ácido Tereftalilideno Dicânfora Sulfônico e seus sais • Benzofenona-4 e seus sais • Benzofenona-3 • Antranilato de metila • Padimato O • Óxido de zinco, e suas misturas.[0033] The preferred UV filters are selected from the group consisting of: • Avobenzone • Homosalate • Octissalate • Octocylene • 2-Ethylexil p-methoxycinnamate • Isoamil p-methoxycinnamate • 3- (4'-methylbenzylidene) -d, l-camphor • 2,4,6-trianilino (p-carbo-2'-ethylexil-1'-oxy) -1,3,5-triazine • Tris-Biphenyl Triazine • Diethylexil Butamido Triazone • Benzylidenomalonate-polysiloxane • 2-ethylhexyl 4-dimethylaminobenzoate • Drometrizole trisiloxane • Bis-Ethylexyloxyphenol Methoxyphenyl Triazine • 2,2'-Methylenebis (6- (2H-benztriazol-2-yl) -4-1,1,3,3-tetramethylbutyl) -phenol), • Diethylamino Hydroxybenzoyl Hexyl Benzoate • Disodium Phenyl-dibenzimidazole Tetrasulfonate and its salts • Phenylbenzimidazole-sulfonic acid and its salts • Sulfonic Terephthalilidene Acid and its salts • Benzophenone-4 and its salts • Benzophenone-3 • Methyl anthranylate • Padimato O • Zinc oxide, and their mixtures.
[0034] [0034] The cosmetic or pharmaceutical compositions according to the invention can comprise other auxiliaries and additives selected from surfactants, oily bodies, emulsifiers, coemulsifiers, super-greasing agents, pearlization waxes, consistency factors, polymers, silicone compounds, waxes, stabilizers , anti-dandruff agents, film-forming agents, swelling agents, hydrotropes, preservatives, solubilizers, complexing agents, reducing agents, alkalinizing agents, perfume oils, dyes, thickeners, fats, lecithins, phospholipids, humectants, biogenic agents, antioxidants, deodorants, antiperspirants, insect repellents, self-tanning agents, tyrosine inhibitors (depigmentation agents), embedding agents, biogenic active ingredients, antimicrobial agents, antifoams, pigments that have a coloring action, aqueous and non-aqueous plant extracts, and more as auxiliary and additives adi nationals.
[0035] [0035] The cosmetic and / or pharmaceutical preparations according to the invention, preferably dermatological preparations, comprising the coated titanium dioxide particles of the invention, have a sun protection factor of at least 2. It is possible to use the dioxide particle titanium coating of the present invention in all cosmetic or pharmaceutical preparations with the total possible sun protection factor, likewise 10, 15, 20, 25, 30 or 50.
[0036] [0036] In a preferred embodiment, cosmetic or pharmaceutical preparations, preferably dermatological preparations, have a UVA protection factor of at least 2, measured by the Colipa Method for in vitro determination of UVA protection, 2011 or the strictly related ISO standard 24443-2012 Determination of sunscreen UVA photo protection in vitro.
[0037] [0037] Cosmetic and / or pharmacological preparations, preferably dermatological preparations, for the protection of human skin against the harmful effects of UV radiation, comprising the coated titanium dioxide of the invention alone or in combination with other UV attenuating agents.
[0038] [0038] In another preferred embodiment of the invention, a preparation (cosmetic and / or pharmaceutical, preferably dermatological) comprises a total amount of UV filters and / or inorganic pigments such that the preparation of the invention has a greater or equal sun protection factor to 2 (preferably greater than or equal to 5). These sunscreens are suitable for protecting skin and hair.
[0039] [0039] Furthermore, suitable photoprotective agents (UV absorbers) for cosmetic and / or pharmaceutical, preferably dermatological, preparation of the present invention are, for example, organic UV absorbers of the class of 4-aminobenzoic acid and derivatives, salicylic acid derivatives, benzophenone derivatives, dibenzoylmethane derivatives, diphenylacrylates, 3-imidazol-4-ylacrylic acid and its esters, benzofuran derivatives, benzylidenomalonate derivatives, polymeric UV absorbers containing one or more organosilicon radicals, acid derivatives cinnamic, camphor derivatives, trianilino-s-triazine derivatives, 2-hydroxyphenylbenzotriazole derivatives, menthyl anthranilate, benzotriazole derivatives and indole derivatives.
[0040] [0040] The UV absorbers specified below, which can be used additionally for the purposes of the present invention, are preferable, but of course are not limiting. The preferred UV filters are:
[0041] • Ácido P-aminobenzoico • p-aminobenzoato de etila (25 mol) etoxilado • p-dimetilaminobenzoato de 2-etilexila • salicilato de homomentila (homosalato) (Neo Heliopan®HMS) • salicilato de 2-etilexila (Neo Heliopan®OS) • salicilato de trietanolamina (Neo Heliopan® TS) • antranilato de mentila (Neo Heliopan®MA) • p-metoxicinamato de 2-etilexila (Neo Heliopan®AV) • p-metoxicinamato de isoamila (Neo Heliopan®E 1000) • ácido 2-fenilbenzimidazol sulfônico (Neo Heliopan® Hydro) e seus sais • sulfato de 3-(4'-trimetilamônio)benzilidenobornan-2-ona metila • 3-(4'-sulfo)benzilidenobornan-2-ona e sais • 3-(4'-metilbenzilideno)-d,l-cânfora (Neo Heliopan®MBC) • Polímero de N-[(2 e 4)-[2-(oxoborn-3-ilideno)metil]benzil]acrilamida • 4,4’-[(6-[4-(1,1-dimetil)aminocarbonil)fenilamino]-1,3,5-triazina2,4-diil)diimino]bis(éster 2-etilexílico de ácido benzoico) (Uvasorb®HEB) • benzilidenomalonato-polissiloxano (Parsol®SLX) • tris(2-etilexil) 4,4´,4´´-(1,3,5-triazina-2,4,6-triiltriimino)tribenzoato (Uvinul®T150) • 2-ciano-3,3-difenilacrilato de 2-etilexila (Neo Heliopan®303) [0041] UVB filters: • P-aminobenzoic acid • ethoxylated ethyl p-aminobenzoate (25 mol) • 2-ethylhexyl p-dimethylaminobenzoate • homomenthyl salicylate (homosalate) (Neo Heliopan®HMS) • 2-ethylhexyl salicylate (Neo Heliopan®OS) • triethanolamine salicylate (Neo Heliopan® TS) • menthol anthranilate (Neo Heliopan®MA) • 2-ethylhexyl p-methoxycinnamate (Neo Heliopan®AV) • isoamyl p-methoxycinnamate (Neo Heliopan®E 1000) • 2-phenylbenzimidazole sulfonic acid (Neo Heliopan® Hydro) and its salts • methyl 3- (4'-trimethylammonium) benzylidenobornan-2-one sulfate • 3- (4'-sulfo) benzylidenobornan-2-one and salts • 3- (4'-methylbenzylidene) -d, l-camphor (Neo Heliopan®MBC) • N - [(2 and 4) - [2- (oxoborn-3-ylidene) methyl] benzyl] acrylamide polymer • 4,4 '- [(6- [4- (1,1-dimethyl) aminocarbonyl) phenylamino] -1,3,5-triazine2,4-diyl) diimino] bis (benzoic acid 2-ethylexyl ester) ( Uvasorb®HEB) • benzylidenomalonate-polysiloxane (Parsol®SLX) • tris (2-ethylexil) 4,4´, 4´´- (1,3,5-triazine-2,4,6-triyltriimino) tribenzoate (Uvinul®T150) • 2-ethylhexyl 2-cyano-3,3-diphenylacrylate (Neo Heliopan®303)
[0042] • ácido 2-hidróxi-4-metoxibenzofenona-5-sulfônico (sulisobenzona, benzofenona-4) ou seus sais. • 2-hidróxi-4-metoxibenzofenona (Neo Heliopan® BB, Oxibenzona, benzofenona-3) • 2,2’-dihidróxi-4,4’-dimetóxi-5,5’-dissulfobenzofenona de dissódio • fenol,-(2H-benzotriazol-2-il-4-metil-6-(2-metil-3-(1,3,3,3-tetrametil1-(trimetilsilil)óxi)dissiloxianil)propil), (Mexoryl ®XL) • 2,2’-metilenobis(6-(2H-benztriazol-2-il)-4-1,1,3,3-tetrametilbutil)- fenol), Tinosorb®M) • 2,4-bis[4-(2-etilexilóxi)-2-hidroxifenil]-1,3,5-triazina • 2,4-bis[{(4-(2-etilexilóxi)-2-hidróxi}fenil]-6-(4-metoxifenil)-1,3,5- triazina, (Tinosorb®S) • Tris-Bifenil Triazina (Tinosorb® A2B) • sal de 2,4-bis[{(4-(3-sulfonato)-2-hidroxipropilóxi)-2-hidróxi}fenil]- 6-(4-metoxifenil)-1,3,5-triazina sódico • 2,4-bis[{(3-(2-propilóxi)-2-hidroxipropilóxi)-2-hidróxi}fenil]-6-(4- metoxifenil)-1,3,5-triazina • 2,4-bis[{4-(2-etilexilóxi)-2-hidróxi}fenil]-6-[4-(2-metoxietilcarbonil)fenilamino]-1,3,5-triazina • 2,4-bis[{4-(3-(2-propilóxi)-2-hidroxipropilóxi)-2-hidróxi}fenil]-6-[4- (2-etilcarboxil)fenilamino]-1,3,5-triazina • 2,4-bis[{4-(2-etilhexilóxi)-2-hidróxi}fenil]-6-(1-metilpirrol-2-il)-1,3,5- triazina • 2,4-bis[{4-tris(trimetilsiloxissililpropilóxi)-2-hidróxi}fenil]-6-(4- metoxifenil)-1,3,5-triazina • 2,4-bis[{4-(2‘‘-metilpropenilóxi)-2-hidróxi}fenil]-6-(4-metoxifenil)- 1,3,5-triazina • 2,4-bis[{4-(1‘,1‘,1‘,3‘,5‘,5‘,5‘-heptametilsilóxi-2‘‘-metilpropilóxi)- 2-hidróxi}fenil]-6-(4-metoxifenil)-1,3,5-triazina. [0042] Wide band filters: • 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid (sulisobenzone, benzophenone-4) or its salts. • 2-hydroxy-4-methoxybenzophenone (Neo Heliopan® BB, Oxybenzone, benzophenone-3) • 2,2'-dihydroxy-4,4'-dimethoxy-5,5'-disulfobenzophenone • phenol, - (2H-benzotriazol-2-yl-4-methyl-6- (2-methyl-3- (1,3,3,3-tetramethyl1- (trimethylsilyl) oxy) disiloxyanyl) propyl), (Mexoryl ® XL) • 2,2'-methylenebis (6- (2H-benztriazol-2-yl) -4-1,1,3,3-tetramethylbutyl) -phenol), Tinosorb®M) • 2,4-bis [4- (2-ethylhexoxy) -2-hydroxyphenyl] -1,3,5-triazine • 2,4-bis [{(4- (2-ethylexyloxy) -2-hydroxy} phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine, (Tinosorb®S) • Tris-Biphenyl Triazine (Tinosorb® A2B) • 2,4-bis [{(4- (3-sulfonate) -2-hydroxypropyloxy) -2-hydroxy} phenyl] - 6- (4-methoxyphenyl) -1,3,5-triazine salt • 2,4-bis [{(3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy} phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine • 2,4-bis [{4- (2-ethylhexyl) -2-hydroxy} phenyl] -6- [4- (2-methoxyethylcarbonyl) phenylamino] -1,3,5-triazine • 2,4-bis [{4- (3- (2-propyloxy) -2-hydroxypropyloxy) -2-hydroxy} phenyl] -6- [4- (2-ethylcarboxyl) phenylamino] -1,3,5- triazine • 2,4-bis [{4- (2-ethylhexyloxy) -2-hydroxy} phenyl] -6- (1-methylpyrrol-2-yl) -1,3,5-triazine • 2,4-bis [{4-tris (trimethylsiloxysilylpropyloxy) -2-hydroxy} phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine • 2,4-bis [{4- (2 '' - methylpropenyloxy) -2-hydroxy} phenyl] -6- (4-methoxyphenyl) - 1,3,5-triazine • 2,4-bis [{4- (1 ', 1', 1 ', 3', 5 ', 5', 5'-heptamethylsiloxy-2 '' - methylpropyloxy) - 2-hydroxy} phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine.
[0043] • ácido tereftalilidenodibornanossulfônico e sais (Mexoryl®SX) • Avobenzona (Neo Heliopan® 357) • 2-(4-dietilamino-2-hidroxibenzoil)benzoato de hexila (Uvinul® A Plus) • Antranilato de mentila (Neo Heliopan®MA) [0043] UVA filters: • terephthalilidenodibornanesulfonic acid and salts (Mexoryl®SX) • Avobenzone (Neo Heliopan® 357) • 2- (4-diethylamino-2-hydroxybenzoyl) hexyl benzoate (Uvinul® A Plus) • Menthyl anthranilate (Neo Heliopan®MA)
[0044] • salicilato de homomentila (Neo Heliopan®HMS) • ácido tereftalilidenodibornanossulfônico e sais (Mexoryl®SX) • 2-etilexil 2-ciano-3,3-difenilacrilato (Neo Heliopan® 303) • polímero de N-[(2 e 4)-[2-(oxoborn-3- ilideno)metil]benzil]acrilamida • p-metoxicinamato de 2-etilexila (Neo Heliopan®AV) • p-aminobenzoato de etila (25 mol) etoxilado • p-metoxicinamato de isoamila (Neo Heliopan®E1000) • ácido 2-fenilbenzimidazol sulfônico (Neo Heliopan® Hydro) e seus sais • 2,4,6-trianilino(p-carbo-2'-etilexil-1'-óxi)-1,3,5-triazina (Uvinul® T150) • fenol,2-(2H-benzotriazol-2-il)-4-metil-6-(2-metil-3(1,3,3,3- tetrametil-1-(trimetilsilil)óxi)disiloxianil)propil), (Mexoryl®XL) • 4,4’-[(6-[4-(1,1-dimetil)aminocarbonil)fenilamino]-1,3,5-triazin-2,4- diil)-diimino]bis(éster 2-etilexílico de ácido benzoico), (Uvasorb ® HEB) • 3-(4'-metilbenzilidene)-d,l-cânfora (Neo Heliopan®MBC) • salicilato de 2-etilexila (Neo Heliopan®OS) • 4-dimetilaminobenzoato de 2-etilexila (Padimate O) • 2-hidróxi-4-metoxibenzofenona (Neo Heliopan® BB, Oxibenzona, benzofenona-3) • 2,2’-metilenobis(6-(2H-benzotriazol-2-il)-4-1,1,3,3-tetrametilbutil)- fenol), (Tinosorb®M) • 2,4-bis[{(4-(2-etilexilóxi)-2-hidróxi}fenil]-6-(4-metoxifenil)-1,3,5- triazina, (Tinosorb®S) • benzilidenomalonato-polissiloxano (Parsol®SLX) • 2-(4-dietilamino-2-hidroxibenzoil)benzoato de hexila (Uvinul® A Plus) • Avobenzona (Neo Heliopan® 357) • antranilato de mentila (Neo Heliopan®MA). [0044] UV absorbers (particularly suitable for combination): • homomenthyl salicylate (Neo Heliopan®HMS) • terephthalilidenodibornanesulfonic acid and salts (Mexoryl®SX) • 2-ethylexyl 2-cyano-3,3-diphenylacrylate (Neo Heliopan® 303) • N - [(2 and 4) - [2- (oxoborn-3-ylidene) methyl] benzyl] acrylamide polymer • 2-ethylhexyl p-methoxycinnamate (Neo Heliopan®AV) • ethoxylated ethyl p-aminobenzoate (25 mol) • isoamyl p-methoxycinnamate (Neo Heliopan®E1000) • 2-phenylbenzimidazole sulfonic acid (Neo Heliopan® Hydro) and its salts • 2,4,6-trianilino (p-carbo-2'-ethylexil-1'-oxy) -1,3,5-triazine (Uvinul® T150) • phenol, 2- (2H-benzotriazol-2-yl) -4-methyl-6- (2-methyl-3 (1,3,3,3-tetramethyl-1- (trimethylsilyl) oxy) disyloxyanyl) propyl), (Mexoryl®XL) • 4,4 '- [(6- [4- (1,1-dimethyl) aminocarbonyl) phenylamino] -1,3,5-triazin-2,4-diyl) -diimino] bis (2-ethylexyl acid ester benzoic), (Uvasorb ® HEB) • 3- (4'-methylbenzylidene) -d, l-camphor (Neo Heliopan®MBC) • 2-ethylhexyl salicylate (Neo Heliopan®OS) • 2-ethylhexyl 4-dimethylaminobenzoate (Padimate O) • 2-hydroxy-4-methoxybenzophenone (Neo Heliopan® BB, Oxybenzone, benzophenone-3) • 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4-1,1,3,3-tetramethylbutyl) -phenol), (Tinosorb®M) • 2,4-bis [{(4- (2-ethylexyloxy) -2-hydroxy} phenyl] -6- (4-methoxyphenyl) -1,3,5-triazine, (Tinosorb®S) • benzylidenomalonate-polysiloxane (Parsol®SLX) • 2- (4-diethylamino-2-hydroxybenzoyl) hexyl benzoate (Uvinul® A Plus) • Avobenzone (Neo Heliopan® 357) • menthol anthranilate (Neo Heliopan®MA).
[0045] [0045] In addition, additional particulate UV filters or inorganic pigments can be used, which if desired can become hydrophobic, such as zinc (ZnO), iron (Fe2O3), zirconium (ZrO2) oxides, silicon (SiO2), manganese (eg MnO), aluminum (Al2O3), cerium (eg Ce2O3) and / or mixtures.
[0046] [0046] The total amount of all sulfonated water-soluble UV filters, such as, but not limited to, phenylbenzimidazole sulfonic acid, and / or Disodium Phenyl Dibenzimidazole Tetrasulfonic acid and / or Benzophenone-4, and / or terephthalylidenodibornanesulfonic acid and / or methyl 3- (4'-trimethylammonium) benzylidenobornan2-one sulfate, and / or 3- (4'-sulfo) benzylidenobornan-2-one, and their salts in cosmetic and pharmaceutical preparations, preferably preparations dermatological, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 15.0% and more particularly in the range of 0.5 to 10.0% and most particularly in the range of 1.0 to 8, 0% of the total formulation.
[0047] [0047] The amount of disodium phenyl dibenzimidazole tetrasulfonate and its salts used in cosmetic and pharmaceutical preparations, preferably dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range of 0.3 to 8% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0048] [0048] The amount of phenylbenzimidazole sulfonic acid and its salts used in cosmetic and pharmaceutical preparations, preferably dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range of 0.3 to 8% and more preferably in the range of 0.5 to 5.0% of the total formulation.
[0049] [0049] The amount of Mexoryl® SX and its salts used in cosmetic and pharmaceutical preparations, preferably dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range from 0.3 to 8% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0050] [0050] The total amount of oil-soluble UV filters that can be used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, for example, but not limited to these (2-ethylexil) 4,4´, 4´´- (1,3,5-triazine-2,4,6-triyltriimino) tribenzoate and / or -tert-butyl-4'-methoxydibenzoylmethane, and / or 2-ethylhexyl 4-dimethylaminobenzoate , and / or Mexoryl®XL and / or Uvasorb®HEB and / or Tinosorb®S and / or Benzophenone-3 and / or Parsol®SLX and / or Neo Heliopan®MA, and / or isoamyl pmetoxicinamate, and / or salicylate of 2-ethylhexyl, and / or homosalate, and / or ethylhexylmethoxycinnamate, and / or octocrylene, and / or Uvinul® A Plus, and / or 3- (4'-methylbenzylidene) -d, l-camphor, 4- 2-ethylexyl dimethylaminobenzoate, is in the range of 0.1 to 55% by weight, particularly in the range of 0.5 to 40%, most particularly in the range of 1 to 30% of the total formulation.
[0051] [0051] The amount of ethylhexyl methoxycinnamate used in cosmetic and pharmaceutical preparations, preferably dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 20.0%, preferably in the range of 0.3 - 15% and the most preferable in the range of 0.5 to 10.0% of the total formulation.
[0052] [0052] The amount of isoamyl p-methoxycinnamate used in cosmetic and pharmaceutical preparations, preferably dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 20.0%, preferably in the range of 0.3 to 15% and most preferable in the range of 0.5 to 10.0% of the total formulation.
[0053] [0053] The amount of Octocrylene used in cosmetic and pharmaceutical preparations, preferably dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 20.0%, preferably in the range of 0.3 to 15% and most preferable in the range of 0.5 to 10.0% of the total formulation.
[0054] [0054] The amount of salicylate esters used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 20.0%, preferably in the range of 0, 3 to 15% and most preferable in the range of 0.5 to 10.0% of the total formulation. When ethylhexyl salicylate is selected as the UV filter, it is advantageous that its total amount varies from 0.1 to 5.0% of the formulation and when homosalate is selected as the UV filter, it is advantageous that its quantity total varies from 0.1 to 15.0% of the formulation.
[0055] [0055] The amount of Avobenzone used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range of 0.3 at 7.0% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0056] [0056] The amount of Uvasorb® HEB used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range of 0 , 3 to 7.0% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0057] [0057] The amount of Uvinul® T-150 used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range from 0.3 to 7.0% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0058] [0058] The amount of 2,4-bis [{(4- (2-ethylexyloxy) -2-hydroxy} phenyl] -6- (4-methoxy-phenyl) -1,3,5-triazine, (Tinosorb® S) used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range of 0.3 to 7.0% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0059] [0059] The amount of 2,2'-methylenebis (6- (2H-benzotriazol-2-yl) -4- 1,1,3,3-tetramethylbutyl) -phenol), (TinosorbⓇM) used in cosmetic preparations and pharmaceutical, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, preferably in the range of 0.3 to 7.0% and most preferably in the range of 0.5 to 5.0% of the total formulation.
[0060] [0060] The amount of Tris-biphenyl triazine (Tinosorb® A2B), used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0% , preferably in the range of 0.3 to 7.0% and most preferably in the range of 0.5 to 5.0% of the total formulation.
[0061] [0061] The amount of benzylidenomalonate-polysiloxane (Parsol®SLX) used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide of the invention, is in the range of 0.1 to 10.0%, from preferably in the range of 0.3 to 7.0% and most preferable in the range of 0.5 to 5.0% of the total formulation.
[0062] [0062] The total amount of organic and / or inorganic microfine pigments, for example, but not limited to these, derivatives of triazine and / or zinc oxide (coated and uncoated), and / or titanium dioxide (coated or uncoated) ) which can be used in cosmetic and pharmaceutical preparations, preferably in dermatological preparations, comprising the coated titanium dioxide particles of the invention, is in the range of 0.1 to 35%, preferably in the range of 0.3 to 25% and more preferably in the range of 0.5 to 15.0% and most preferably in the range of 0.75% to 10.0%. When titanium dioxide is selected as the UV filter, it is advantageous that its total amount varies between 0.1% and 10.0% of the formulation. When zinc oxide is selected as the UV filter, it is advantageous that its total amount varies between 0.1% and 10.0% of the formulation and when one or more organic triazine pigments are chosen, it is advantageous that their total amount varies from 0.1% to 10.0% of the formulation.
[0063] [0063] The combination of the coated titanium particles of the invention with additional UV filters, for example, with the UV filters as described above and particularly with the UV filters which are described as "particularly suitable for combination", leads to synergistic effects the degree of protection offered against UVB and UVA radiation as determined by the measures to determine the sun protection factors against UVA and / or UVB radiation.
[0064] [0064] Thus, the combination of the coated titanium particles of the invention with one or more of the UV filters described above, as well as any UV filters permitted for use in solar protection products legislated in the Europe: by Cosmetics regulation (EC) No 1223/2009 of the Council of European Communities published in the in the Official Journal of the European Communities. Australia: on the positive list of permitted UV filters published by the Australian Therapeutic Goods Administration in the Australian Register of Therapeutic Goods (ARTG).
[0065] [0065] In addition, it is advantageous to add one or more of the highly photostable UV absorbers, selected from methylbenzylidene camphor, 2-ethylhexyl-2-cyano-3,3'-diphenylacrylate, octyltriazone, Uvasorb®HEB, ethylhexyl salicylate, salicylate homomentyl, phenylbenzimidazolsulfonic acid, Benzophenone-3, Mexoryl®SX, Mexoryl®XL, Tinosorb® S, Tinosorb® M, Tinsorb® A2B, Neo Heliopan® AP, or Parsol®SLX, or mixtures thereof.
[0066] [0066] In the case where one of the UV filters is Avobenzone, it is advantageous to add a photostabilizing emollient such as 2,6-diethylexyl naphthalate sold under the trade name of Symrise Corapan® TQ, to improve the photostability of Avobenzone.
[0067] [0067] The synergies of titanium dioxide coated with cetearyl nonanoate together with other constituents that do not absorb UV light, with regard to better protection against sunlight, should be expected in cosmetic, dermatological and pharmacological preparations, for example. example, but not limited to: polymers, emulsifiers (anionic, cationic, zwitterionic, nonionic, quaternary), thickeners, rheology modifiers, C2 to C50 alkyl esters (branched or linear) or aromatic alkyl esters (branched or linear), triols or their esters, glycols or their esters, monohydric alcohols or their esters, waxes, silicone derivatives, chelating agents, preservatives, vitamins and their derivatives, tanning agents, tanning accelerators, skin whitening or whitening agents, amino acids and their derivatives, peptides and their derivatives, carotenoids and their derivatives, anti-inflammatory ingredients, fragrances, ag cooling or heating entities and insect repellents, flavonoids, antioxidants, plant extracts, and non-nano-sized pigments (colored or white).
[0068] [0068] Cosmetic and / or pharmaceutical preparations, in particular the dermatological preparations according to the invention can be formulated in the usual way and preferably serve as cosmetic and pharmaceutical sunscreens, particularly as dermatological sunscreens and also for the treatment, care and cleaning skin and / or hair, and as a make-up product in decorative cosmetics.
[0069] [0069] The cosmetic and / or pharmaceutical preparations, in particular the dermatological preparations according to the invention, serve to protect the skin and hair against UV radiation, can be in the forms of use conventionally used, that is, in the form of oil in water, water in oil or mixed emulsion, in milky form, in the form of lotion or cream, aerosol, hydrodispersion gel or oily gel (free of emulsifier), spray, foam, solution, powder, pencil preparation or in the form any other usual cosmetic and pharmaceutical preparations (particularly dermatological). Preparations such as shampoo, rinse, conditioner, gel, lotion, spray or cream are preferably used to protect the hair from UV rays.
[0070] [0070] Cosmetic and / or pharmaceutical preparations, in particular the dermatological preparations according to the invention can have the usual composition and can be used for cosmetic and / or dermatological sun protection, and also for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics. Consequently, the preparations according to the present invention can, depending on their formulation, be used, for example, as a skin protection cream, milky cleansing lotion, sun protection lotion, nourishing cream, day cream or night cream . The preparations according to the present invention can, depending on their formulation, also be used, for example, in compositions for the treatment of hair such as shampoos, conditioners, 2-in-1 preparations, anti-dandruff shampoos, hair tonics, hair lotions, ridges hair, styling products, sprays, etc. In some cases, it is possible and advantageous to use the preparations according to the present invention as bases for pharmaceutical preparations. Preference is given, in particular, to those cosmetic and dermatological preparations in the form of a skin care product, hair treatment or makeup. Typical embodiments are creams, gels, for example, but not limited to them, hydrogels, hydrodispersion gels, oily gels; lotions alcoholic and aqueous / alcoholic solutions, emulsions in their various forms, for example, but not limited to, oil in water (O / W), water in oil (W / O), mixed emulsions, PIT emulsions, Pickering emulsions, microemulsions, nanoemulsions; aerosol foams, non-aerosol foams, aerosol sprays, non-aerosol sprays, pump sprays, serums, roll-ons, pastes, balms, or stick preparations.
[0071] [0071] The pharmaceutical and cosmetic preparations of the present invention are preferably dermatological preparations, which are preferably administered to the skin and / or hair.
[0072] [0072] The cosmetic or pharmaceutical preparations according to the invention can comprise as auxiliary and additives surfactants, oily bodies, emulsifiers, coemulsifiers, super-greasing agents, pearlization waxes, consistency factors, polymers, silicone compounds, waxes, stabilizers, anti-dandruff agents, film-forming agents, swelling agents, hydrotropes, preservatives, solubilizers, complexing agents, reducing agents, alkalinizing agents, perfume oils, dyes, thickeners, fats, lecithins, phospholipids, humectants, biogenic agents, antioxidants, deodorants, antiperspirants , insect repellents, self-tanning agents, tyrosine inhibitors (depigmentation agents), embedding agents, biogenic active ingredients, antimicrobial agents, antifoams, pigments that have a coloring action, aqueous and non-aqueous plant extracts, and others more like additional auxiliaries and additives .
[0073] [0073] Preferably, the cosmetic and pharmaceutical preparations, in particular the dermatological preparations according to the present invention, are applied to the skin and / or hair in an amount sufficient in the usual manner for cosmetics or pharmaceutical and dermatological preparations.
[0074] [0074] The cosmetic or pharmaceutical preparations according to the invention, preferably in the form of a dermatological preparation, are preferably selected from the group consisting of creams, gels, hydrogels, hydrodispersion gels, oily gels, lotions, balms. COSMETIC AND PHARMACEUTICAL PREPARATIONS
[0075] [0075] The cosmetic and pharmaceutical preparations according to the present invention can include similar additives, such as, for example, oily bodies or emulsifiers. Therefore, the boundary between cosmetic and pharmaceutical preparations is in flux and it should be understood that the components mentioned for an application are recommended for other mutatis-mutandis without literal repetition. Surfactants
[0076] • tensoativos aniônicos, • tensoativos catiônicos, • tensoativos anfotéricos e • tensoativos não iônicos. [0076] The preferred modalities of cosmetic and pharmaceutical preparations, especially dermatological ones of the invention, can also comprise anionic, cationic, nonionic and / or amphoteric surfactants (included in the term surfactant is the term emulsifier). Surfactants are amphiphilic substances that can dissolve or disperse non-polar organic substances in water. In this context, the hydrophilic components of a surfactant molecule are generally polar functional groups, for example, -COO-, -OSO32-, -SO3-, while the hydrophobic parts as a rule are non-polar hydrocarbon radicals. Surfactants are generally classified according to the nature and charge of the hydrophilic molecular component. A distinction can be made here between the four groups: • anionic surfactants, • cationic surfactants, • amphoteric surfactants and • non-ionic surfactants.
[0077] • ácidos de acilamino (e seus sais), tais como: • glutamatos de acila, por exemplo, glutamato de acil sódico, aspartato de di-TEA-palmitoíla e glutamato caprílico/cáprico de sódio, • peptídeos de acila, por exemplo, proteína do leite hidrolisada por palmitoíla, proteína de soja hidrolisada por cocoíla de sódio e colágeno hidrolisado por cocoíla de sódio/potássio, • sarcosinatos, por exemplo, sarcosina de miristoíla, sarcosinato de TEA-lauroíla, lauroil sarcosinato de sódio e cocoil sarcosinato de sódio, • tauratos, por exemplo, lauroil taurato de sódio e metilcocoil taurato de sódio, • lactilatos de acila, lactilato de lauroíla, lactilato de caproíla • alaninatos • ácidos carboxílicos e derivados, tais como, por exemplo: estearato de TEA, estearatos de glicerila, estearatos de PEG glicerila, ácido láurico, estearato de alumínio, alcanolato de magnésio e undecilenato de zinco, • ácidos carboxílicos de éster, por exemplo: estearoil lactilato de cálcio, citrato de laureth-6 e PEG-4 lauramida carboxilato de sódio, estearatos de glicerila, gliceril-oleilestearatos, citratos de glucerila, oleil citratos de glicerila, • ácidos carboxílicos de éter, por exemplo, laureth-13 carboxilato de sódio e PEG-6 cocoamida carboxilato de sódio, • Ésteres de glicosídeo, tais como, por exemplo: • cetearil glicosídeo, lauril glicosídeo • ésteres e sais de ácido fosfórico, tais como, por exemplo: fosfato de cetila (mono, di cetila e suas misturas), cetil fosfato de potássio, (mono, di cetila e suas misturas), cetil fosfato de DEA (mono, di cetil e suas misturas), DEA -oleth-10 fosfato e dilaureth-4 fosfato, • ácidos sulfônicos e sais, tais como isetionatos de acila, por exemplo, cocoil isetionato de sódio/amônio, alquilarilsulfonatos, • alquilsulfonatos, por exemplo, sulfato de coco-monoglicerídeo sódico, olefinsulfonato C12-14 de sódio, lauril sulfoacetato de sódio e PEG-3 cocamida sulfato de magnésio, • sulfossuccinatos, por exemplo, sulfossuccinato de dioctil sódio, lauret-sulfossuccinato de dissódio, laurilsulfossuccinato de dissódio e undecilenamido-MEA-sulfossuccinato de dissódio e • ésteres de ácido sulfúrico, tais como: sulfato de éter alquílico, por exemplo, sódio, amônio, magnésio, MIPA, TIPA laureth sulfato, mireth sulfato de sódio e pareth sulfato C12-13 de sódio, • sulfatos de alquila, por exemplo, sódio, amônio e sulfato de TEA laurila. [0077] Anionic surfactants as a rule contain groups of carboxylate, sulfate or sulfonate as functional groups. In aqueous solution, they form negatively charged organic ions in an acidic or neutral medium. Cationic surfactants are almost exclusively characterized by the presence of a group of quaternary ammonium. In aqueous solution, they form positively charged organic ions in an acidic or neutral medium. Amphoteric surfactants contain both anionic and cationic groups and consequently behave as anionic or cationic surfactants in aqueous solution, depending on the pH. In a strongly acidic medium they have a positive charge, and in an alkaline medium they have a negative charge. On the other hand, they are zwiterionics in the neutral pH range. Polyether and polysaccharide chains are typical of nonionic surfactants. Nonionic surfactants do not form ions in an aqueous medium. Specifically useful are: • acylamino acids (and their salts), such as: • acyl glutamates, for example, sodium acyl glutamate, di-TEA-palmitoyl aspartate and caprylic / capric sodium glutamate, • acyl peptides, for example, milk protein hydrolyzed by palmitoyl, soy protein hydrolyzed by sodium cocoyl and collagen hydrolyzed by sodium / potassium cocoyl, • sarcosinates, for example, myristoyl sarcosine, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate, • taurates, for example, sodium lauroyl taurate and sodium methylcocoil taurate, • acyl lactylates, lauryl lactylate, caproil lactylate • alaninates • carboxylic acids and derivatives, such as, for example: TEA stearate, glyceryl stearates, PEG glyceryl stearates, lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate, • ester carboxylic acids, for example: calcium stearoyl lactylate, laureth-6 citrate and sodium PEG-4 lauramide carboxylate, glyceryl stearates, glyceryl-oleylstearates, gluceryl citrates, glyceryl oleyl citrates, • ether carboxylic acids, for example, sodium laureth-13 carboxylate and sodium PEG-6 cocoamide carboxylate, • Glycoside esters, such as, for example: • cetearyl glycoside, lauryl glycoside • phosphoric acid esters and salts, such as, for example: cetyl phosphate (mono, di cetyl and mixtures thereof), potassium cetyl phosphate, (mono, di cetyl and mixtures thereof), DEA cetyl phosphate (mono, di cetyl and mixtures thereof), DEA -oleth-10 phosphate and dilaureth-4 phosphate, • sulfonic acids and salts, such as acyl isethionates, for example, sodium / ammonium cocoyl isethionate, alkylarylsulfonates, • alkylsulfonates, for example, sodium coconut monoglyceride sulphate, sodium C12-14 olefinsulfonate, sodium lauryl sulfoacetate and PEG-3 cocamide magnesium sulphate, • sulfosuccinates, for example, sodium dioctyl sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido-MEA-sulfosuccinate and • sulfuric acid esters, such as: alkyl ether sulfate, for example, sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, mireth sodium sulfate and sodium pareth sulfate C12-13, • alkyl sulfates, for example, sodium, ammonium and TEA lauryl sulfate.
[0078] • alquilaminas, • alquilimidazóis, • aminas etoxiladas, • tensoativos quaternários, • RNH2CH2CH2COO-(no pH = 7) • RNHCH2CH2COO- B+ (no pH = 12) B+= qualquer cátion desejado, por exemplo, Na+ e • esterquats. [0078] The cationic surfactants that are advantageously used are • alkylamines, • alkylimidazoles, • ethoxylated amines, • quaternary surfactants, • RNH2CH2CH2COO- (at pH = 7) • RNHCH2CH2COO- B + (at pH = 12) B + = any desired cation, for example, Na + and • esterquats.
[0079] [0079] Quaternary surfactants contain at least one N atom that is covalently linked to 4 alkyl or aryl groups. This leads to a positive charge, regardless of pH. Alkylbetaine, alkylamidopropylbetaine and alkylamidopropylhydroxysulfaine are advantageous. The cationic surfactants used can also be selected from the group consisting of quaternary ammonium compounds, in particular benzyltrialkylammonium chlorides or bromides, such as, for example, benzyldimethylstearylammonium chloride, and also alkyltrialkylammonium salts, for example, cetyltrimethylammonium chloride or bromide , alkylldimethylhydroxyethylammonium chlorides or bromides, dialkyldimethylammonium chlorides or bromides, alkylamideethyltrimethylammonium ether sulphates, alkylpyridinium salts, for example, lauryl or cetylpyridinium chloride, imidazoline derivatives and such compounds having an amine character for example, alkyldimethylamine oxides or alkylaminoethyldimethylamine oxides. Cetyltrimethylammonium salts in particular are advantageously used.
[0080] • acila/dialquiletilenodiamina, por exemplo, acilanfoacetato de sódio, acilanfodipropionato dissódico, alquilanfodiacetato dissódico, acilanfoidroxipropilsulfonato de sódio, acilanfodiacetato dissódico e acilanfopropionato de sódio, • ácidos de N-alquilamino, por exemplo, aminopropil alquilglutamida, ácido alquilaminopropiônico, alquilimidodipropionato de sódio e lauroanfocarboxiglicinato, • acilanfoidroxipropilsulfonato, acilanfodiacetato dissódico e acilanfopropionato de sódio, • ácidos de N-alquilamino, por exemplo, aminopropil alquilglutamida, ácido alquilaminopropiônico, alquilimidodipropionato de sódio e lauroanfocarboxiglicinato. [0080] The amphoteric surfactants that are advantageously used are: • acyl / dialkylethylenediamine, for example, sodium acylamphodipropionate, disodium acylamphodipropionate, disodium alkylamphodiacetate, sodium acylaminohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acylamphopropionate, • N-alkylamino acids, for example, aminopropyl alkylglutamide, alkylaminopropionic acid, sodium alkylimidipropionate and lauroanfocarboxyglycinate, • acylanfohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acylanphopropionate, • N-alkylamino acids, for example, aminopropyl alkylglutamide, alkylaminopropionic acid, sodium alkylimidipropionate and lauroanfocarboxyglycinate.
[0081] • álcoois, • alcanolamidas, tais como cocamidas MEA/DEA/MIPA, • óxidos de amina, tais como óxido de cocoamidopropilamina, • éteres, por exemplo, álcoois etoxilados/propoxilados, ésteres etoxilados/propoxilados, ésteres de glicerol etoxilados/propoxilados, colesteróis etoxilados/propoxilados, ésteres de triglicerídeo etoxilados/propoxilados, lanolina etoxilada/propoxilada, polissiloxanos etoxilados/propoxilados, éteres de POE propoxilados e poliglicosídeos de alquila, tais como lauril glicosídeo, decil glicosídeo e coco-glicosídeo. • ésteres de sacarose, éteres de sacarose • ésteres de poliglicerol, ésteres de diglicerol, ésteres monoglicerol poligliceril-2 dipoliidroxiestearato (Dehymuls®PGPH), poligliceril-3 diisoestearato (Lameform®TGI), poligliceril-4 isoestearato (Isolan®GI 34), poligliceril-3 oleato, diisostearil poligliceril-3 diisoestearato (Isolan®PDI), poligliceril-3 metilglucose diestearato (Tego Care®450), poligliceril-3 de cera de abelha (Cera Bellina®), poligliceril-4 caprato (poliglicerol caprato T2010/90), éter poligliceril-3 cetílico (Chimexane®NL), poligliceril-3 diestearato (Cremophor®GS 32), poligliceril-2 estearato (Hostacerin®DGMS) e poligliceril polirricineoleato (Admul®WOL 1403), e suas misturas. • ésteres de metilglicose, ésteres de ácidos de hidróxi. [0081] The non-ionic surfactants that are advantageously used are • alcohols, • alkanolamides, such as cocamides MEA / DEA / MIPA, • amine oxides, such as cocoamidopropylamine oxide, • ethers, for example, ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterols, ethoxylated / propoxylated ethoxylated / propoxylated, polyoxylated and propoxylated lanolin esters, polysilated / propoxylated, polysilated alkyl polyglycosides, such as lauryl glycoside, decyl glycoside and coco-glycoside. • sucrose esters, sucrose ethers • polyglycerol esters, diglycerol esters, polyglycerol-2 dipolehydroxystearate esters (Dehymuls®PGPH), polyglyceryl-3 diisoestearate (Lameform®TGI), polyglyceryl-4 isostearate (Isolan®GI-, polyglycyl-, polyglycyl- 3, polyglycyl- 3 diisoestearate (Isolan®PDI), polyglyceryl-3 methylglucose distearate (Tego Care®450), beeswax polyglyceryl-3 (Bellina® Wax), polyglyceryl-4 caprate (polyglycerol caprate T2010 / 90), polyglyceryl-3 cetyl ether (Chimexane®NL), polyglyceryl-3 distearate (Cremophor®GS 32), polyglyceryl-2 stearate (Hostacerin®DGMS) and polyglyceryl poly-ricineoleate (Admul®WOL 1403), and mixtures thereof. • methylglycoside esters, hydroxy acid esters.
[0082] [0082] The use of a combination of anionic and / or amphoteric surfactants with one or more non-ionic surfactants is even more advantageous. Oily bodies
[0083] [0083] Suitable oil bodies, which form constituents of O / W emulsions, are, for example, Guerbet alcohols based on fatty alcohols having 6 to 18, preferably 8 to 10 carbon atoms, esters of C6 linear fatty acids -C22 with C6-C22 linear or branched fatty alcohols or C6-C13 branched carboxylic acid esters with C6-C22 linear or branched fatty alcohols, such as, for example, myristyl myristate, myristyl palmitate, myristyl stearate, isostearate myristyl, myristyl oleate, myristyl beenate, myristyl erucate, cetyl myristate, cetyl palmitate, cetyl stearate, cetyl isostearate, cetyl oleate, cetyl beenate, cetyl erucate, stearyl myristate, stearyl myristate , stearyl stearate, stearyl isostearate, stearyl oleate, stearyl beenate, stearyl erucate, isostearyl myristate, isostearyl palmitate, isostearyl stearate, isostearyl stearate, isostearyl oleate, isostearyl beenate, isostearyl oleate, oleyl myristate, oleyl palmitate, oleyl stearate, oleyl stearate, oleyl oleate, oleyl beate, oleyl erucate, beenila stearate, beenyl stearate, beyl stearate beenila, beenila isostearate, beenila oleate, beenila beenate, beenila erucate, erucila myristate, erucila palmitate, erucila stearate, erucila isostearate, erucila oleate, erucila beenate and erucila erucate. Also suitable are C6-C22 linear fatty acid esters with branched alcohols, in particular 2-ethylexanol, C18-C38-alkylhydroxy carboxylic acid esters with C6-C22 linear or branched fatty alcohols, in particular Dioctyl Malate, fatty acid esters linear and / or branched with polyhydric alcohols (such as, for example, propylene glycol, dimerdiol or trimertriol) and / or Guerbet alcohols, triglycerides based on C6-C10 fatty acids, liquid mono- / di- / triglyceride mixtures in C6-C18 fatty acids, esters of C6-C22 fatty acids and / or Guerbet alcohols with aromatic carboxylic acids, in particular benzoic acid, esters of C2-C12 dicarboxylic acids with linear or branched alcohols having from 1 to 22 carbon atoms or polyols having 2 to 10 carbon atoms and 2 to 6 hydroxyl groups, vegetable oils, branched primary alcohols, substituted cyclohexanes, linear and branched C6-C22 fatty alcohol carbonates, such as, for example example, Dicaprylyl Carbonate (Cetiol® CC), Guerbet carbonates, based on fatty alcohols having from 6 to 18, preferably from 8 to 10, carbon atoms, benzoic acid esters with C6-C22 linear and / or branched alcohols ( Finsolv® TN), linear or branched, symmetrical or asymmetric dialkyl ethers having 6 to 22 carbon atoms per alkyl group, such as, for example, tippryl ether (Cetiol® OE), ring opening products fatty acid esters subjected to epoxy with polyols, silicone oils (cyclomethicone, silicone methicone categories, etc.) and / or aliphatic or naphthenic hydrocarbons, such as, for example, squalane, squalene or dialkylcyclohexanes. Emulsifiers
[0084] • produtos da adição de 2 a 30 moles de óxido de etileno e/ou de 0 a 5 moles de óxido de propileno em álcoois graxos lineares C8-22, em ácidos graxos C12-22 e em fenóis de alquila contendo de 8 a 15 átomos de carbono no grupo de alquila; • monoésteres e diésteres de ácido graxo C12/18 de produtos de adição de 1 a 30 moles de óxido de etileno em glicerol; • mono- e diésteres de glicerol e mono- e diésteres de sorbitano de ácidos graxos saturados e não saturados, contendo de 6 a 22 átomos de carbono e seus produtos de adição de óxido de etileno; • produtos de adição de 15 a 60 moles de óxido de etileno em óleo de rícino e/ou óleo de rícino hidrogenado; • ésteres de poliol e, em particular, ésteres de poliglicerol tais como, por exemplo, polirricinoleato de poliglicerol, poli-12-hidroxiestearato de poliglicerol ou dimerato isoestearato de poliglicerol. As misturas de compostos de várias destas classes também são adequadas; • produtos de adição de 2 a 15 moles de óxido de etileno em óleo de rícino e/ou óleo de rícino hidrogenado; • ésteres parciais com base ácidos graxos C6/22 lineares, ramificados, insaturados ou saturados C6 graxos, ácido ricinoleico e ácido 12- hidroxiesteárico e glicerol, poliglicerol, pentaeritritol, dipentaeritritol, álcoois de açúcar (por exemplo, sorbitol), glicosídeos de alquila (por exemplo, glicosídeo de metila, glicosídeo de butila, glicosídeo de laurila) e poliglicosídeos (por exemplo, celulose); • fosfatos de mono, di e trialquila e fosfatos de mono-, di- e/ou tri-PEGalquila e seus sais; • álcoois de cera de lã; • copolímeros de polissiloxano/poliéter polialquílico e derivados correspondentes; • ésteres misturados de pentaeritritol, ácidos graxos, ácido cítrico e álcool graxo e/ou ésteres misturados de ácidos graxos C6-22, metil glicose e polióis, de preferência glicerol ou o poliglicerol, • glicóis de polialquileno e • carbonato de glicerol. [0084] Other surfactants can also be added to preparations as emulsifiers, including, for example: • products of the addition of 2 to 30 moles of ethylene oxide and / or 0 to 5 moles of propylene oxide in linear fatty alcohols C8-22, in fatty acids C12-22 and in alkyl phenols containing 8 to 15 atoms carbon in the alkyl group; • C12 / 18 fatty acid monoesters and diesters of addition products from 1 to 30 moles of ethylene oxide in glycerol; • glycerol mono- and diesters and sorbitan mono- and diesters of saturated and unsaturated fatty acids, containing from 6 to 22 carbon atoms and their ethylene oxide addition products; • products for the addition of 15 to 60 moles of ethylene oxide in castor oil and / or hydrogenated castor oil; • polyol esters and, in particular, polyglycerol esters such as, for example, polyglycerol polyricinoleate, polyglycerol poly-12-hydroxystearate or polyglycerol isostearate dimerate. Mixtures of compounds from several of these classes are also suitable; • products with the addition of 2 to 15 moles of ethylene oxide in castor oil and / or hydrogenated castor oil; • partial esters based on C6 / 22 linear, branched, unsaturated or saturated C6 fatty acids, ricinoleic acid and 12-hydroxystearic acid and glycerol, polyglycerol, pentaerythritol, dipentaerythritol, sugar alcohols (eg sorbitol), alkyl glycosides ( for example, methyl glycoside, butyl glycoside, lauryl glycoside) and polyglycosides (for example, cellulose); • mono-, di- and trialkyl phosphates and mono-, di- and / or tri-PEGalkyl phosphates and their salts; • wool wax alcohols; • polysiloxane / polyalkyl polyether copolymers and corresponding derivatives; • mixed esters of pentaerythritol, fatty acids, citric acid and fatty alcohol and / or mixed esters of C6-22 fatty acids, methyl glucose and polyols, preferably glycerol or polyglycerol, • polyalkylene glycols and • glycerol carbonate.
[0085] [0085] Products for the addition of ethylene oxide and / or propylene oxide in fatty alcohols, fatty acids, alkylphenols, glycerol mono- and diesters and fatty acid sorbitan mono- and diesters are known products commercially available. They are mixtures of homologues in which the average degree of alkoxylation corresponds to the relationship between the amounts of ethylene oxide and / or propylene oxide and substrate, with which the addition reaction is carried out. The monoesters of C12 / 18 fatty acids and diesters of ethylene oxide addition products in glycerol are known as lipid layer enhancers for cosmetic formulations. Preferred emulsifiers are described in more detail as follows:
[0086] [0086] Partial glycerides. Typical examples of suitable partial glycerides are hydroxystearic acid monoglyceride, hydroxystearic acid diglyceride, isostearic acid monoglyceride, isostearic acid diglyceride, oleic acid monoglyceride, oleic acid diglyceride, ricinoleic acid monoglyceride, ricinoleic acid monoglyceride, diglyceride acid linoleic, linoleic acid diglyceride, linolenic monoglyceride, linolenic diglyceride, erucic acid monoglyceride, erucic acid diglyceride, tartaric acid monoglyceride, tartaric acid diglyceride, citric acid monoglyceride, diglyceric acid, glyclic acid monoglyceride, diglyceric acid malic acid and its technical mixtures that may still contain small amounts of triglyceride from the production process. Addition products 1 to 30 and preferably 5 to 10 moles of ethylene oxide in the mentioned partial glycerides are also suitable.
[0087] [0087] Sorbitan esters. Suitable sorbitan esters are sorbitan monoiso stearate, sorbitan sesquiiso stearate, sorbitan diiso stearate, sorbitan triiso stearate, sorbitan monooleate, sorbitan sesquioleate, sorbitan dioleate, sorbitan trileate, sorbitan monohydrate, sorbitan monohydrate, sorbitan monohydrate sorbitan trierucate, sorbitan monoricinoleate, sorbitan sesquirricinoleate, sorbitan dirricinoleate, sorbitan trirricinoleate, sorbitan monohydroxystearate, sorbitan sesquihydroxystearate, sorbitan dihydrate, sorbitate, sorbitan trihydrate, trihydrate sorbitan, sorbitan monocitrate, sorbitan sesquicitrate, sorbitan dicitrate, sorbitan tritritrate, sorbitan monomaleate, sorbitan sesquimaleate, sorbitan dimaleate, sorbitan trimaleate and their technical mixtures. Addition products 1 to 30 and preferably 5 to 10 moles of ethylene oxide in the mentioned sorbitan esters are also suitable.
[0088] [0088] Polyglycerol esters. Typical examples of suitable polyglycerol esters are Polyglyceryl-2 Dipolyhydroxystearate (Dehymuls® PGPH), polyglycerin-3-diisoestearate (Lameform® TGI), Polyglyceryl-4 isostearate (Isolan® GI 34), Polyglyceryl-3 oleate, Diea Diisoestearato (Isolan® PDI), Poligliceril-3 Methylglicose Diestearato (Tego Care® 450), Poligliceril-3 Beeswax (Bellina® Wax), Polyglyceril-4 Caprate (Polyglycerol Caprate T2010 / 90), Polyglyceryl-3 Cetyl Ether (Chimexane ® NL), Poligliceril-3 Diestearato (Cremophor® GS 32) e Poliglicerila Polirricinoleato (Admul® WOL 1403), Polyglyceril Iso-stearate and mixtures thereof. Examples of other suitable polyolesters are mono-, di- and triesters of trimethylol propane or pentaerythritol with lauric acid, cocoolean acid, tallow fatty acid, palmitic acid, stearic acid, oleic acid, behenic acid and more, optionally reacted with 1 to 30 moles of ethylene oxide.
[0089] [0089] Anionic emulsifiers. Typical anionic emulsifiers are C12-22 aliphatic fatty acids, such as palmitic acid, stearic acid or behenic acid, for example, and C12-22 dicarboxylic acids, such as azelaic acid or sebacic acid, for example.
[0090] [0090] Amphoteric emulsifiers. Other suitable emulsifiers are amphoteric or zwitterionic surfactants. Zwitterionic surfactants are surfactant compounds that contain at least one quaternary ammonium group and at least one carboxylate and a sulfonate group in the molecule. Particularly suitable zwitterionic surfactants are so-called betaines, such as N-alkyl-N, N-dimethyl ammonium glycinates, for example, cocoalkyl dimethyl ammonium glycinate, N-acylaminopropyl-N, N-dimethyl ammonium glycinates, for example example of cocoacylaminopropyl dimethyl ammonium glycinate, and 2-alkyl-3-carboxymethyl-3-hydroxyethyl imidazolines containing 8 to 18 carbon atoms in the alkyl or acyl group and cocoacylaminoethyl hydroxyethyl carboxymethyl glycinate. The fatty acid amide derivative known under the name CTFA of Cocamidopropyl Betaine is particularly preferable. Ampholytic surfactants are also suitable emulsifiers. Ampholytic surfactants are surfactant compounds that, in addition to a C8 / 18 alkyl or acyl group, contain at least one free amino group and at least one -COOH- or - SO3H- group in the molecule and which are capable of forming salts internal. Examples of suitable ampholytic surfactants are N-alkyl glycines, N-alkyl propionic acids, N-alkylaminobutyric acids, Nalkyliminodipropionic acids, N-hydroxyethyl-N-alkylamidopropyl glycines, N-alkyl taurines, N-alkyl sarcosines, 2-alkylaminopropionic acids and alkyl-aminoaminoacetic acids and alkyl acids around 8 to 18 carbon atoms in the alkyl group. Particularly preferred ampholytic surfactants are N-cocoalkylaminopropionate, cocoacylaminoethyl aminopropionate and C12 / 18 acyl sarcosine. Super fatty agents and consistency factors
[0091] [0091] Super fatty agents can be selected from such substances as, for example, lanolin and lecithin and also derivatives of lanolin and lecithin polyethoxylated or acylated, esters of polyol fatty acids, monoglycerides and alkanolamides of fatty acid, alkanolamides of fatty acid which also serve as foam stabilizers.
[0092] [0092] The consistency factors mainly used are fatty alcohols or hydroxy fatty alcohols containing from 12 to 22 and preferably from 16 to 18 carbon atoms and also partial glycerides, fatty acids or hydroxy fatty acids. A combination of these substances with alkyl oligoglycosides and / or N-methyl glucamides of fatty acid of the same chain length and / or polyglycerol poly-12-hydroxystearates, is preferably used. Thickeners and rheology additives
[0093] [0093] Suitable thickeners are polymeric thickeners, such as types of Aerosil® (hydrophilic silicas), polysaccharides, more especially xanthan gum, guar guar, agar agar, alginates and tiloses, carboxymethyl cellulose and hydroxyethyl cellulose, also monoesters and relatively high molecular weight polyethylene glycol diesters of fatty acids, polyacrylates (eg Carbopols® [Goodrich] or Synthalens® [Sigma]), polyacrylamides, polyvinyl alcohol and polyvinyl pyrrolidone, surfactants such as, for example, fatty acid glycerides ethoxylates, fatty acid esters with polyols, for example, pentaerythritol or trimethylol propane, narrow-range fatty alcohol ethoxylates and electrolytes such as sodium chloride and ammonium chloride. Polymers
[0094] [0094] Suitable cationic polymers are, for example, cationic cellulose derivatives such as, for example, quaternized hydroxyethyl cellulose obtained from Amerchol under the name Polymer JR 400®, cationic starch, dialkyl ammonium and copolymer salts copolymers, quaternized vinyl pyrrolidone / vinyl imidazole polymers, such as, for example, Luviquat® (BASF), condensation products of polyglycols and amines, quaternized collagen polypeptides such as, for example, Lauryldimonium Hydroxypropyl Hydrolyzed Collagen (Lamequat® L, Grünau) , quaternized wheat polypeptides, polyethyleneimine, cationic silicone polymers such as, for example, amodimethicone, adipic acid and dimethylaminohydroxypropyl diethylene triamine copolymers (Cartaretine®, Sandoz), acrylic acid copolymers with dimethyl methyl ammonium chloride (550) , polyamino polyamides and their cross-linked water-soluble polymers, cationic chitin derivatives such as, for example, quaternized chitosan, optionally in microcrystalline distribution, condensation products of dialoalkyls, for example, dibromobutane, with bisdialkylamines, for example, bis-dimethylamino-1,3-propane, cationic guar gum such as, for example, Jaguar®CBS, Jaguar ®C-17, Jaguar®C-16 by Celanese, quaternized ammonium salt polymers such as, for example, Mirapol® A-15, Mirapol® AD-1, Mirapol® AZ-1 by Miranol and the various types of polyquaternium (for example 6, 7, 32 or 37) that can be found on the market under the trade names Rheocare® CC or Ultragel® 300.
[0095] [0095] Suitable anionic, zwitterionic, amphoteric and non-ionic polymers are, for example, vinyl acetate / crotonic acid copolymers, vinyl pyrrolidone / vinyl acrylate copolymers, vinyl acetate / butyl maleate copolymers / isobornyl acrylate , copolymers of methyl vinyl ether / maleic anhydride and their esters, polyacrylic acids, non-cross-linked and cross-linked with polyol, copolymers of acrylamidopropyl trimethylammonium / acrylate chloride, methyl octyl acrylate / methacrylacrylate, methyl acetate / acrylate, polyacrylate and acrylate , vinyl acetate pyrrolidone / vinyl copolymers, vinyl pyrrolidone / dimethylaminoethyl methacrylate / vinyl caprolactam terpolymers and optionally derivatized cellulose ethers and silicones. Beading waxes
[0096] [0096] Suitable beading waxes are, for example, alkylene glycol esters, especially ethylene glycol distearate; fatty acid alkanolamides, especially the cocog fatty acid diethanolamide; partial glycerides, especially stearic acid monoglycerides; esters of polybasic carboxylic acids optionally hydroxysubstituted with fatty alcohols containing from 6 to 22 carbon atoms, especially long chain esters of tartaric acid; fatty compounds, such as, for example, fatty alcohols, fatty ketones, fatty aldehydes, fatty ethers and fatty carbonates that contain a total of at least 24 carbon atoms, especially laurone and distearylether; fatty acids such as stearic acid, hydroxystearic acid or behenic acid, olefin epoxide ring opening products containing 12 to 22 carbon atoms with fatty alcohols containing 12 to 22 carbon atoms and / or polyols containing 2 to 15 carbon atoms and 2 to 10 hydroxyl groups and their mixtures. Silicones
[0097] Suitable silicone compounds are, for example, dimethyl polysiloxanes, methylphenyl polysiloxanes, cyclic silicones, and silicone compounds modified by amino, fatty acid, alcohol, polyether, epoxy, fluorine, glycoside and / or alkyl which can be both liquid and resin-like at room temperature. Other suitable silicone compounds are simethicones which are mixtures of dimethicones with an average chain length of 200 to 300 units of dimethylsiloxane and hydrogenated silicates. Waxes and stabilizers
[0098] [0098] In addition to the natural oils used, waxes can also be present in preparations, more especially natural waxes such as, for example, candelilla wax, carnauba wax, Japan wax, broad grass wax, cork wax, wax of guaruma, rice oil wax, sugar cane wax, ouricuri wax, montana wax, beeswax, shellac wax, spermaceti, lanolin (wool wax), uropigial fat, ceresin, ozocerite ( earth wax), petroleum jelly, paraffin waxes and microceras; chemically modified waxes (hard waxes), such as, for example, montana ester waxes, sasol waxes, hydrogenated jojoba waxes and synthetic waxes such as, for example, polyalkylene waxes and polyethylene glycol waxes.
[0099] [0099] Metal salts of fatty acids such as, for example, magnesium, aluminum and / or zinc stearate or ricinoleate, can be used as stabilizers. Cooling agents
[0100] [00100] The compositions may also contain one or more substances with a physiological cooling effect (cooling agents), which are preferably selected here from the following list: menthol and menthol derivatives (for example, L-menthol, D -mentol, racemic menthol, isomentol, neoisomentol, neomentol), menthol glycerol acetal (trade name: Frescolat®MGA), menthol lactate (trade name: Frescolat®ML, menthol lactate is preferably l-mentila lactate, in particular l -l-menthyl lactate), menthyl ethyl starch oxalate (Frescolat® X-Cool), menthyl ethers (eg (I-mentoxy) -1,2-propanediol, (l-mentoxy) -2-methyl-1,2 -propanediol, l-menthyl-methylether), menthyl esters (for example, menthylformate, menthylacetate, menthylisobutyrate, mentillactates, L-mentyl-L-lactate, L-mentyl-D-lactate, menthyl- (2-methoxy) acetate, menthyl - (2-methoxyethoxy) acetate, menthylpyroglutamate), menthylcarbonates (for example, menthylpropylene glycolcarbonate, menthyl ethylene glycolcarbonate, m entylglycerolcarbonate or mixtures thereof), the half esters of menthols with a dicarboxylic acid or its derivatives (for example, mono-menthyl succinate, mono-menthylglutarate, monomentylmalonate, O-mentyl succinic acid ester-N, N- (dimethyl) amide, ester amide of O-menthyl succinic acid), mentanocarboxylic acid amides (in this case preferably N-ethylamide [WS3] or Nα- (mentanocarbonyl) glycinetylester [WS5], as described in US 4,150,052, mentanocarboxylic-N- (4- cyanophenyl) amide or mentanecarboxylic acid-N- (4-cyanomethylphenyl) amide as described in WO 2005 049553 A1, methanecarboxylic acid-N- (alkoxyalkyl) amides), menthol and menthol derivatives (eg, L-mentone glycerol ketal), derivatives of 2,3-dimethyl-2- (2-propyl) butyric acid (for example, 2,3-dimethyl-2- (2-propyl)-butyric-N-methylamide [WS23]), isopulegol or their compounds esters (I- (-) - isopulegol, I - (-) - isopulegolacetate), derivatives of mentane (for example p-menthane-3,8-diol), baseball or synthetic or natural mixtures containing cubball, pyrrolidone derivatives of cycloalkyldione derivatives (for example, 3-methyl-2 (1-pyrrolidinyl) -2-cyclopentene-1-one) or tetrahydropyrimidine-2-one (for example, iciline or related compounds, as described in WO 2004/026840), other carboxamides (for example, N- (2- (pyridin-2-yl) ethyl) -3-p-mentanecarboxamide or related compounds), (1R, 2S, 5R) -N- (4-Methoxyphenyl) -5-methyl-2- (1-isopropyl) cyclohexane-carboxamide [WS12], oxamates (preferably those described in EP 2033688 A2).
[0101] [00101] The use concentration of the active cooling compounds to be used is, depending on the substance, preferably in the concentration range between 0.01% to 20% by weight, and more preferably in the concentration range of 0.1% to 5% by weight, based on the total weight of the completed cosmetic and pharmaceutical (dermatological) preparations (ready to use). The following examples are intended to illustrate the present invention without restricting it. All quoted quantities, proportions and percentages are, unless otherwise stated, based on the weight and the total quantity or the total weight of the preparations. Antimicrobial agents
[0102] [00102] Suitable antimicrobial agents are, in principle, all substances effective against Gram-positive bacteria, such as, for example, 4-hydroxybenzoic acid and its salts and esters, N- (4-chlorophenyl) -N'- (3,4-dichlorophenyl) urea, 2,4,4'-trichloro-2'-hydroxydiphenyl ether (triclosan), 4-chloro-3,5-dimethyl-phenol, 2,2'-methylenebis (6-bromo4- chlorophenol), 3-methyl-4- (1-methylethyl) phenol, 2-benzyl-4-chloro-phenol, 3- (4-chlorophenoxy) -1,2-propanediol, 3-iodo-2-propynyl butylcarbamate, chlorhexidine , 3,4,4'-trichlorocarbanilide (TTC), antibacterial fragrances, thymol, thyme oil, eugenol, clove oil, menthol, mint oil, farnesol, phenoxyethanol, glycerol monocaprate, glycerol monocaprilate, glycerol monolaurate ( GML), diglycerol monocaprate (DMC), salicylic acid N-alkylamides, such as, for example, n-octylsalicylamide or n-decylsalicylamide. Enzyme inhibitors
[0103] [00103] Suitable enzyme inhibitors are, for example, esterase inhibitors. These are preferably trialkyl citrates, such as trimethyl citrate, tripropyl citrate, triisopropyl citrate, tributyl citrate and, in particular, triethyl citrate (Hidagen CAT). The substances inhibit the activity of the enzyme, thus reducing the formation of odor. Other substances which are suitable esterase inhibitors are sterol sulphates or phosphates, such as, for example, lanosterol sulphate or phosphate, cholesterol, campesterol, stigmasterol and sitosterol, dicarboxylic acids and their esters, such as, for example, glutaric acid, monoethyl glutarate, diethyl glutarate, adipic acid, monoethyl adipate, diethyl adipate, malonic acid and diethyl malonate, and hydroxycarboxylic acids and their esters, such as, for example, citric acid, malic acid, tartaric acid or tartrate diethyl, and zinc glycinate. Odor absorbers and antiperspirant active agents
[0104] [00104] Suitable odor absorbers are substances that are capable of absorbing and largely retaining odor-forming compounds. They reduce the partial pressure of the individual components, thus also reducing their diffusion rate. It is important that perfumes must remain intact in this process. Odor absorbers are not effective against bacteria. They comprise, for example, as a main constituent, a complex zinc salt of ricinoleic acid or specific, fragrances largely of neutral odor that are known to the person skilled in the art as "fixatives", such as, for example, extracts of labdanum or stirax or certain derivatives of abietic acid. Odor masking agents are scents or perfume oils, which, in addition to their function as odor masking agents, provide their respective deodorant fragrance notes. The perfume oils that can be mentioned are, for example, mixtures of natural and synthetic fragrances. Natural fragrances are extracts from flowers, stems and leaves, fruits, fruit peels, roots, woods, herbs and grasses, needles and branches, and resins and balms. Also suitable are products of animal origin, such as, for example, civet and beaver. Typical synthetic fragrance compounds are ester, ether, aldehyde, ketone, alcohol and hydrocarbon products. Ester-type fragrance compounds are, for example, benzyl acetate, p-tert-butylcyclohexyl acetate, linalyl acetate, phenylethyl acetate, linalyl benzoate, benzyl formate, allyl cyclohexylpropionate, styryl propionate and salicylate benzyl. Ethers include, for example, benzyl ethyl ether, and aldehydes include, for example, linear alkanes having 8 to 18 carbon atoms, citral, citronellal, citronyloxyacetaldehyde, cyclamen aldehyde, hydroxycitronellal, lilial and bourgeonal, ketones include, for example For example, ionones and cedryl methyl ketone, alcohols include anethole, citronelol, eugenol, isoeugenol, geraniol, linaool, phenylethyl alcohol and terpineol, and hydrocarbons mainly include terpenes and balms. The preference is, however, given to the use of mixtures of different fragrances that together produce a pleasant fragrance note. Essential oils of relatively low volatility, which are mainly used as aroma components, are also suitable as perfume oils, for example, sage oil, chamomile oil, clove oil, melissa oil, peppermint oil, leaf oil cinnamon oil, linden flower oil, Juniperberry oil, vetiver oil, frankincense oil, galbanum oil, labdanum oil and lavender oil. Preference is given to the use of bergamot oil, dihydromyrcenol, lilial, liral, citronelol, phenylethyl alcohol, αhexylcinamaldehyde, geraniol, benzylacetone, cyclamen aldehyde, linalool, strong boisambrene, ambroxan, indole, hedione, sandelice, lemon oil, oil orange oil, allyl amyl glycolate, cyclovertal, lavender oil, sage oil, β-damask, conservative geranium oil, cyclohexyl salicylate, Vertofix coeur, iso-E-super, Fixolide NP, evernila, gamma iraldein, acid phenylacetic, geranyl acetate, benzyl acetate, rose oxide, romilat, irotil and floramat alone or in mixtures.
[0105] [00105] Suitable astringent antiperspirant active ingredients are mainly aluminum, zirconium or zinc salts. Such suitable anti-hydrotic active ingredients are, for example, aluminum chloride, aluminum chloride, aluminum dihydrochloride, aluminum sesquichlorohydride and their complex compounds, for example, with 1,2-propylene glycol, aluminum hydroxyalanthinate, tartrate chloride aluminum, aluminum zirconium trichloride, aluminum zirconium tetrachloride, aluminum zirconium pentachloride and their complex compounds, for example, with amino acids, such as glycine. Film-forming and anti-dandruff agents
[0106] [00106] Standard film formers are, for example, chitosan, microcrystalline chitosan, quaternized chitosan, polyvinyl pyrrolidone, vinyl pyrrolidone / vinyl acetate copolymers, acrylic acid series polymers, quaternary cellulose derivatives, collagen, hyaluronic acid and its salts and similar compounds.
[0107] Suitable anti-dandruff agents are Pirocton Olamin (1-hydroxy-4-methyl-6- (2,4,4-trimethylpentyl) -2- (1H) -pyridinone monoethanolamine salt), Baipival® (Climbazole), Ketoconazole ® (4-acetyl-1- {4- [2- (2,4-dichlorophenyl) r-2- (1H-imidazol-1-ylmethyl) -1,3-dioxylan-c-4-ylmethoxyphenyl} - piperazine, ketoconazole, elubiol, selenium disulphide, colloidal sulfur, sulfur mono-oleate polyethylene glycol sorbitan, sulfur polyethoxylate ricinol, tar sulfur distillate, salicylic acid (or in combination with hexachlorophene), undecylenic acid, monoethanolamide sulphate Lamepon® UD (protein condensate / undecylenic acid), zinc pyrithione, aluminum pyrithione and magnesium pyrithione / magnesium dipyrithone sulfate. Vehicles and hydrotropes
[0108] [00108] Preferred cosmetic carrier materials are solid or liquid at 25 ° C and 1013 mbar (including highly viscous substances), such as, for example, glycerol, 1,2-propylene glycol, 1,2-butylene glycol, 1 , 3-propylene glycol, 1,3-butylene glycol, ethanol, water and mixtures of two or more of said liquid carrier materials with water. Optionally, these preparations according to the invention can be produced using preservatives or solubilizers. Other preferred liquid-bearing substances, which can be a component of a preparation according to the invention, are selected from the group consisting of oils such as vegetable oil, neutral oil and mineral oil.
[0109] [00109] Preferred solid carrier materials, which can be a component of a preparation according to the present invention, are hydrocolloids, such as starches, starches, degraded starches, chemically or physically modified starches, dextrins, maltodextrins (powder) ( preferably with an equivalent dextrose value of 5 to 25, preferably of 10 to 20), lactose, silicon dioxide, glucose, modified celluloses, gum arabic, ghatti gum, tragacanth, caraia, carrageenan, pullulan, curdlan, gum xanthan, gelan gum, guar flour, locust bean flour, alginates, agar, pectin and inulin and mixtures of two or more of these solids, in particular maltodextrins (preferably with a dextrose equivalent value of 15 to 20), lactose , silicon dioxide and / or glucose.
[0110] • glicerol; • alquileno glicóis tais como, por exemplo, etileno glicol, dietileno glicol, propileno glicol, butileno glicol, hexileno glicol e polietileno glicol com um peso molecular médio de 100 a 1000 Daltons; • misturas técnicas de oligoglicerol com um grau de autocondensação de 1,5 a 10, tais como, por exemplo, misturas técnicas de diglicerol com um teor de diglicerol de 40 a 50 % em peso; • compostos de metilol tais como, em particular, trimetilol etano, trimetilol propano, trimetilol butano, pentaeritritol e dipentaeritritol; • glicosídeos de alquila inferiores, particularmente aqueles contendo de 1 a 8 átomos de carbono no grupo de alquila, por exemplo, glicosídeo de metila e butila; • álcoois de açúcar contendo de 5 a 12 átomos de carbono, por exemplo, sorbitol ou manitol, • açúcares contendo de 5 a 12 átomos de carbono, por exemplo, glicose ou sacarose; • açúcares de amino, por exemplo, glucamina; • dialcoolaminas, tais como dietanolamina ou 2-aminopropano-1,3-diol. [00110] In addition, hydrotropes, for example, ethanol, isopropyl alcohol or polyols, can be used to improve flow behavior. Suitable polyols preferably contain from 2 to 15 carbon atoms and at least two hydroxyl groups. Polyols can contain other functional groups, most especially amino groups, or they can be modified with nitrogen. Typical examples are • glycerol; • alkylene glycols such as, for example, ethylene glycol, diethylene glycol, propylene glycol, butylene glycol, hexylene glycol and polyethylene glycol with an average molecular weight of 100 to 1000 Daltons; • technical mixtures of oligoglycerol with a degree of self-condensation of 1.5 to 10, such as, for example, technical mixtures of diglycerol with a content of diglycerol of 40 to 50% by weight; • methylol compounds such as, in particular, trimethylol ethane, trimethylol propane, trimethylol butane, pentaerythritol and dipentaerythritol; • lower alkyl glycosides, particularly those containing 1 to 8 carbon atoms in the alkyl group, for example, methyl and butyl glycoside; • sugar alcohols containing 5 to 12 carbon atoms, for example, sorbitol or mannitol, • sugars containing 5 to 12 carbon atoms, for example, glucose or sucrose; • amino sugars, for example, glucamine; • dialcoolamines, such as diethanolamine or 2-aminopropane-1,3-diol.
[0111] [00111] Suitable preservatives are, for example, phenoxyethanol, formaldehyde solution, parabens, pentanediol or sorbic acid and the other classes of compounds listed in Appendix 6, Parts A and B of the Kosmetikverordnung ("Cosmetics Directive"). Perfume oils and fragrances
[0112] [00112] Suitable perfume oils are mixtures of natural and synthetic perfumes. Natural perfumes include flower extracts (lily, lavender, rose, jasmine, neroli, ylang-ylang), stems and leaves (geranium, patchouli, petitgrain), fruits (anise, coriander, cumin, juniper), fruit peel ( bergamot, lemon, orange), roots (nutmeg, angelica, celery, cardamom, cost, iris, calmus), wood (pine, sandalwood, guava, cedar, rosewood), herbs and grasses (tarragon, grass -lemon, sage, thyme), needles and branches (spruce, spruce, pine, dwarf pine), resins and balms (galbanum, elemi, benzoin, myrrh, frankincense, opoponax). Raw materials of animal origin, for example, civet and beaver, can also be used. Typical synthetic perfume compounds are products of the type ester, ether, aldehyde, ketone, alcohol and hydrocarbon. Examples of ester-type perfume compounds are benzyl acetate, phenoxyethyl isobutyrate, p-tert-butyl cyclohexylacetate, linalyl acetate, dimethyl benzyl carbinyl acetate, phenyl ethyl acetate, linalyl benzoate, benzyl formate, ethylmethyl glycinate phenyl, allyl cyclohexyl propionate, styryl propionate and benzyl salicylate. Ethers include, for example, benzyl ethyl ether while aldehydes include, for example, linear alkanes containing 8 to 18 carbon atoms, citral, citronellal, citronyloxyacetaldehyde, cyclamen aldehyde, hydroxycitronellal, lilial and bourgeonal. Examples of suitable ketones are ionones, isomethionone and methyl cedryl ketone. Suitable alcohols are anethole, citronelol, eugenol, isoeugenol, geraniol, linalool, phenylethyl alcohol and terpineol. Hydrocarbons mainly include terpenes and balms. However, it is preferred to use mixtures of different perfume compounds which, together, produce a pleasant perfume. Other suitable perfume oils are essential oils of relatively low volatility, which are used mainly as aroma components. Examples are sage oil, chamomile oil, clove oil, melissa oil, mint oil, cinnamon leaf oil, lemon flower oil, juniper oil, vetiver oil, frankincense oil, galbanum, labdanum oil and lavendin oil. The following are preferably used individually or in the form of mixtures: bergamot oil, dihydromyrcenol, lilial, liral, citronellol, phenylethyl alcohol, hexylcinamaldehyde, geraniol, benzyl acetone, cyclamen aldehyde, linalool, Bois-ambrene Forte, Ambroxan, indole, hedione, sandelice, citrus oil, tangerine oil, orange oil, allylamyl glycolate, cyclovertal, lavendin oil, sclera oil, damask, conservative geranium oil, cyclohexyl salicylate, Vertofix Coeur, Iso-ESuper, Fixolide NP, evernil, gamma iraldein, phenylacetic acid, geranyl acetate, benzyl acetate, rose oxide, romilat, irotil and floramat. Dyes
[0113] [00113] Suitable dyes are all substances suitable and authorized for cosmetic purposes as listed, for example, in the publication "Kosmetische Färbemittel" of the Farbstoffkommission der Deutschen Forschungsgemeinschaft, Verlag Chemie, Weinheim, 1984, pages 81 to 106. Examples include cochineal red A (CI 16255), patent blue V (CI 42051), indigotin (CI 73015), chlorophyllin (CI 75810), quinoline yellow (CI 47005), titanium dioxide (CI 77891), indanthrene blue RS (CI 69800) and madder lake (CI 58000). Luminol can also be present as a luminescent dye. Advantageous colored pigments are, for example, titanium dioxide, mica, iron oxides (for example, Fe2O3, Fe3O4, FeO (OH)) and / or tin oxide. Advantageous dyes are, for example, carmine, Berlin blue, chromium oxide green, ultramarine blue and / or manganese violet.
[0114] [00114] The preferred compositions according to the present invention are selected from the group of products for the treatment, protecting, caring and cleaning the skin and / or hair or as a make-up product, preferably as a leave-on product (the which means that the one or more compounds of formula (I) remain in the skin and / or hair for a longer period of time, in comparison with products without rinsing, so that hydration and / or anti-aging and / or the healing of wounds that promote its action is more pronounced).
[0115] [00115] The formulations according to the invention are preferably in the form of an emulsion, for example, W / O (water in oil), O / W (oil in water), W / O / W (water in emulsion) emulsion oil in water), O / W / O (oil in water in oil), PIT emulsion, Pickering emulsion, emulsion with a low oil content, micro or nanoemulsion, a solution, for example, in oil (fatty oils or esters of fatty acid, in particular, C2-C30 esters of C6-C32 fatty acid) or silicone oil, dispersion, suspension, cream, lotion or milky lotion, depending on the production method and ingredients, a gel (including hydrogel, gel hydrodispersion, oleogel), spraying (for example, pump spraying or propellant spraying) or a foam or impregnating solution for cosmetic wipes, a detergent, for example, soap, synthetic detergent, washing liquid, bath preparation shower and bath, bath product (capsule, oil, tablet, salts, bath salts, soap, etc.), effervescent preparation, a skin care product such as, for example, an emulsion (as described above), ointment, paste, gel (as described above), oil, balm, serum, powder (for example face powder, body powder), a mask, a pencil, stick, roll-on, pump, aerosol (foaming, non-foaming or post-foaming), a deodorant and / or antiperspirant, mouthwash and mouthwash, a foot care product (including keratolytic , deodorant), an insect repellent, a sunscreen, after-sun preparation, a shaving product, aftershave balm, pre- and aftershave lotion, a epilating agent, a hair treatment product such as example, shampoo (including 2 in 1 shampoo, anti-dandruff shampoo, baby shampoo, dry scalp shampoo, concentrated shampoo), conditioner, hair tonic, hair water, hair rinse, styling cream, ointment, hair perm and fixing lotion, hair spray, styling aid (for example, gel or wax), styling agent hair straightening (detangling agent, relaxing), hair dye such as, for example, temporary direct dyeing hair dye, semi-permanent hair dye, permanent hair dye, hair conditioner, hair mousse, hair treatment product eye, makeup, makeup remover or baby product.
[0116] [00116] The formulations according to the invention are particularly preferably in the form of an emulsion, in particular in the form of an emulsion of W / O, O / W, W / O / W, O / W / O, emulsion of TIP, Pickering emulsion, low oil emulsion, or micro or nanoemulsion, a gel (including hydrogel, hydrodispersion gel, oleogel), a solution, for example, in oil (fatty oils or fatty acid esters, in particular C2-C30 esters of C6-C32 fatty acid) or silicone oil, or a spray (for example, pump spray or propellant spray).
[0117] [00117] Auxiliary substances and additives that can be included in quantities of 5 to 99% of body weight, preferably of 10 to 80% of body weight, based on the total weight of the formulation. The amounts of cosmetic or dermatological auxiliary agents and additives and the perfume to be used in each case can be easily determined by the person skilled in the art by simple trial and error, depending on the nature of the particular product.
[0118] [00118] The preparations can also contain water in an amount of up to 99% of body weight, preferably from 5 to 80% of body weight, based on the total weight of the preparation. It should be noted that the information on additives and their ranges for cosmetic compositions is also valid for pharmaceutical or dermatological formulations. Anti-irritation agents
[0119] An important group of coactive agents includes anti-irritant agents such as, for example, steroidal anti-inflammatory substances of the type of corticosteroids, such as, for example, hydrocortisone, hydrocortisone derivatives, such as hydrocortisone 17-butyrate, dexamethasone, phosphate dexamethasone, methylprednisolone or cortisone; non-steroidal anti-inflammatory drugs such as oxicams, such as piroxicam or tenoxicam; salicylates, such as aspirin, Disalcid, Solprin or fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac; fenomenates, such as mefenamic, meclofenamic, flufenamic or niflumic; propionic acid derivatives, such as ibuprofen, naproxen or benoxaprofen, or pyrazoles, such as phenylbutazone, oxyphenylbutazone, febrazone or azapropazone. Alternatively, natural anti-inflammatory substances or reddening and / or itch-relieving substances can be used. Plant extracts, specific fractions of highly active plant extract and highly pure active substances isolated from plant extracts, can be used as extracts, fractions and active substances of aloe vera, Commiphora species, Rubia species, Rubus species, willow, rose-bay, willow leaves, oats, marigold, arnica, St. John's wort, honeysuckle, ginger, chamomile, rosemary, sage, melissa, Passiflora incarnata, Sophora japonica, witch hazel, Pueraria, Dianthus or Echinacea, as well as pure substances such as inter alia, bisabolol, apigenin, apigenin-7-glycoside, rosmarinic acid, boswelic acid, phytosterols, glycyrrhizic acid, glabridine, Licochalcone A, [6] -paradol, and anthranilic acid amides, such as, in particular, avenantramides or diantramides , are particularly preferable. The total amount of anti-irritants in a formulation or product according to the invention is preferably in the range of 0.0001 to 20% by weight, preferably from 0.0001 to 10% by weight, in particular from 0.001 to 5% by weight, based on the total weight of the formulation or product, respectively.
[0120] [00120] Particular useful coactive agents are selected from the group consisting of antimycotics and pain-relieving agents, and more particularly the group consisting of erythromycin, dimethindene, betamethasone, ibuprofen, ketoprofen, diclofenac, metronidazole, acyclovir, imimoquod, terbinafine , docosanol, cyclopyroxolamine, and mixtures thereof:
[0121] [00121] Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people who have an allergy to penicillin.
[0122] [00122] Recent studies have also shown that it can be used as a mild antidepressant. For respiratory tract infections, it has the best coverage of atypical organisms, including mycoplasma and legionellosis. It was first introduced to the market by Eli Lilly and Company, and is now commonly known as EES (erythromycin ethyl succinate, an ester prodrug that is commonly administered). In the structure, this macrocyclic compound contains a 14-membered lactone ring with ten asymmetric centers and two sugars (L-cladinosis and D-desosamine), making it a very difficult compound to produce using synthetic methods. Erythromycin is produced from an actinomycete strain Saccharopolispora erithraea (see US 2,653,899 - Eli Lilly).
[0123] [00123] Dimethindene, also known as Fenistil (RSdimethyl (2- (3- [yridin-2-yl) ethyl] -1H-inden-2-yl) ethyl) amine) is an antihistamine / anticholinergic used orally and locally as an antipruritic.
[0124] [00124] Betamethasone (8S, 9R, 10S.11S, 13S, 14S, 16S, 17R) -9-fluoro-11,17- (2-hydroxyacetyl) -10,13,16-trimethyl6,7,8,9, 10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta (alpha) - phenanthren-3-one) is a potent glucocorticoid steroid with anti-inflammatory and immunosuppressive properties.
[0125] [00125] Unlike other drugs with these effects, betamethasone does not cause water retention. It is applied as a topical cream, ointment, foam, lotion or gel for the treatment of itching. Betamethasone phosphate sodium is sometimes prescribed as an intramuscular (IM) injection for allergies to various foods, including allergic reactions to poison ivy and similar plants (see US 3,053,865 - Merck).
[0126] [00126] Ibuprofen (RS) -2- (4- (2-methylpropyl) phenyl) propanoic acid from the nomenclature iso-butyl-propanoic-phenolic acid is a non-steroidal anti-inflammatory drug (NSAID) used for the relief of arthritis symptoms, fever, as an analgesic (pain reliever), especially where there is an inflammatory component, and dysmenorrhea.
[0127] [00127] Ibuprofen is known to have an antiplatelet effect, although it is relatively mild and somewhat short-lived when compared to aspirin or other more well-known antiplatelet drugs. In general, ibuprofen also acts as a vasoconstrictor, having been shown to constrict coronary arteries and some other blood vessels, mainly because it inhibits the vasodilation prostacyclin produced by the enzymes cyclooxygenase 2. Ibuprofen was derived from propaneic acid by the research division from Boots Group during the 1960s and was patented in 1961. Originally marketed as Brufen, ibuprofen is available under a variety of popular brands, including Motrin, Nurofen, Advil and Nuprin (see US 3,385,886 - Boots).
[0128] [00128] Ketoprofen acid (RS) 2- (3-benzoylphenyl) -propionic is another of the propionic acid class of non-steroidal anti-inflammatory drug (NSAID) with analgesic and antipyretic effects.
[0129] [00129] It works by inhibiting the body's production of prostaglandins (see US 3,641,127 - Rhone-Poulenc).
[0130] [00130] Diclofenac is also a non-steroidal anti-inflammatory drug (NSAID) taken to reduce inflammation and as an analgesic that reduces pain under certain conditions.
[0131] [00131] The name is derived from its chemical name: 2- (2,6-dichloranilino) phenylacetic acid. In the United Kingdom, India, Brazil and the United States, it can be supplied as the sodium or potassium salt, in China, most of the time as the sodium salt, while in some other countries only as the potassium salt. Diclofenac is available as a generic drug in several formulations. Open use (OTC) is approved in some countries for continuing secondary pain and pain and fever associated with common infections (see US 3,558,690 - Ciba-Geigy).
[0132] [00132] Metronidazole (2- (2-methyl-5-nitro-1H-imidazol-1-yl) ethanol) is a nitroimidazole antibiotic medication used particularly for anaerobic and protozoan bacteria.
[0133] [00133] Metronidazole is an antibiotic, amoebicide, and antiprotozoa. It is the drug of choice for the first episodes of mild to moderate Clostridium difficile infection. It is marketed in the USA by Pfizer and globally by Sanofiunder the trade name Flagyl, in Pakistan and Bangladesh also as Nidagyl by Star Laboratories, and in Thailand, as Mepagyl by Thai Nak-horn Patana. It is also marketed in the United Kingdom by Milpharm Limited and Almus Pharmaceuticals. Metronidazole was developed in 1960. Metronidazole is also used as a gel preparation in the treatment of dermatological conditions such as rosaceae and fungal tumors (see US 2,944,061 - Rhone Poulenc).
[0134] [00134] (VIII) Acyclovir (USAN, ex BAN), chemical name acycloguanosine (2-amino-1,9-dihydro-9 - ((2-hydroxyethoxy) methyl) -6H-purin-6-one), abbreviated as ACV is a guanosine analog antiviral drug, marketed under the trade names such as Cyclovir, Herpex, Acivir, Acivirax, Zovirax and Xovir. The solid active agent has a solubility in water (20 ° dH) at 20 ° C of less than 5 g / L.
[0135] [00135] One of the most commonly used antiviral drugs; it is mainly used to treat infections by the herpes simplex virus, as well as in the treatment of varicella zoster (chickenpox) and herpes zoster (herpes zoster); see also US 4,199,574 (Wellcome).
[0136] [00136] Imiquimod (3- (2-methylpropyl) -3,5,8- triazathriciclo [7.4.0.0.2,6] trideca-1 (9), 2 (6), 4,7,10,12-hexaen -7-amine, INN) is a prescription medication that acts as an immune response modifier.
[0137] [00137] It is marketed by Meda AB, Graceway Pharmaceuticals and iNova Pharmaceuticals under the trade names Aldara and Zyclara, and by Mochida as Beselna. It is also referred to as R837 (see US 4,689,338 - Riker).
[0138] [00138] Terbinafine, more particularly terbinafine hydrochloride, [(2E) -6,6-dimethylpt-2-en-4-in-1-yl] (methyl) (naphthalen-1-ylmethyl) amine) is an antifungal agent synthetic allylamine from Novartis. It is highly lipophilic in nature and tends to accumulate in the skin, nails and greasy tissues.
[0139] [00139] It is sold by the name Lamisil in Argentina, Australia, Belgium, Brazil, Canada, Chile, Egypt, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Mexico, Pakistan, Peru, New Zealand, Norway, Romania, Russia, Slovenia, South Africa, Sweden, United Kingdom, United States and Venezuela, also sold under the name Corbinal and Terbisil in Turkey and under the name "undofen cream" in Poland. As a generic it is sold under the name of Zabel in Australia. It is also available as a generic drug in the United States, United Kingdom, Belgium, Switzerland and Brazil. In India, terbinafine hydrochloride is available in topical form under the brand name Sebifin (Ranbaxy Labs), Zimig (GSK Pharma) and mycoCeaze (Progres Laboratories). MycoVa, developed by Apricus Biosciences, is a topical nail solution of terbinafine and DDAIP that completed three Phase III studies for the treatment of onychomycosis (see US 4,755,534 - Sandoz).
[0140] [00140] Docosanol, also known as beenyl alcohol, is a saturated fatty alcohol traditionally used as an emollient, emulsifier and thickener in cosmetics, nutritional supplement (as an individual entity and also as a component of policosanol), and more recently, in a pharmaceutical product approved by the Food and Drug Administration (FDA), Abreva, approved as an antiviral agent for reducing the duration of cold sores caused by the herpes simplex virus.
[0141] [00141] Cyclopyroxolamine (6-cyclohexyl-1-hydroxy-4-methylpyridin2 (1H) -one), also called Batrafen, Loprox, Mycoster, Penlac and Stieprox, is a synthetic antifungal agent for the topical dermatological treatment of superficial mycoses.
[0142] [00142] It is more useful against Tinea versicolor (see US 3,883,545 - Marck). Anti-cellulite agents
[0143] [00143] Agents that enhance or reinforce the activity of anti-cellulite agents, in particular agents that stimulate and / or depolarize C nerve fibers, are preferably selected from the group consisting of capsaicin and its derivatives, vanylyl-nonilamid and its derivatives, L- carnitine, coenzyme A, isoflavonoids, soy extracts, pineapple extract and conjugated linoleic acid. Fat-raising agents
[0144] [00144] The formulations and products according to the present invention can also comprise one or more fat-increasing and / or adipogenic agents, as well as agents for increasing or enhancing the activity of fat-increasing agents. A fat-raising agent is, for example, hydroxymethyloxyphenyl propylmethylmethoxybenzofuran (trade name: Sym3D ™). Hair growth activators or inhibitors
[0145] [00145] The formulations and products according to the present invention can also comprise one or more hair growth activators, that is, agents to stimulate hair growth. Hair growth activators are preferably selected from the group consisting of pyrimidine derivatives, such as 2,4-diaminopyrimidine-3-oxide (Aminexil), 2,4-diamino-6-piperidinopyrimidine-3-oxide (Minoxidil) and its derivatives, 6-amino-1,2-dihydro-1-hydroxy-2-imino-4-piperidinopyrimidine and its derivatives, xanthine alkaloids such as caffeine, theobromine and theophylline and their derivatives, quercetin and derivatives, dihydroquercetin (taxifoline) and derivatives, potassium channel openers, antiandrogenic agents, synthetic or natural 5-reductase inhibitors, nicotinic acid esters such as tocopheryl nicotinate, benzyl nicotinate and C1-C6 alkyl nicotinate, proteins such as, for example, LysPro-Val tripeptide, difencipren, hormones, finasteride, dutasteride, flutamide, bicalutamide, pregnane derivatives, progesterone and their derivatives, cyproterone acetate, spironolactone and other diuretics, calcineurin inhibitors such as FK506 (Tacroli mus, Fujimycin) and its derivatives, cyclosporin A and its derivatives, zinc and zinc salts, polyphenols, procyanidins, proanthocyanidins, phytosterols such as, for example, beta-sitosterol, biotin, eugenol, (±) -beta-citronelol, panthenol, glycogen, for example, from mussels, microorganism extracts, algae, plants and plant parts from, for example, the dandelion genera (Leontodon or Taraxacum), Orthosiphon, Vitex, Coffea, Paullinia, Theobroma, Asiasarum, Cucurbita or Stiphnolobium, Serenoa repens (Saw Palmetto), Sophora flavescens, Pigeum africanum, Panicum miliaceum, Cimicifuga racemosa, Glycine max, Eugenia caryophyllata, Cotinus coggygria, Hibiscus rosa-sinensis, Camellia sinensis, cactus, apple tree, hops and / or rice or wheat hydrolysates.
[0146] Alternatively, formulations and products according to the present invention can comprise one or more hair growth inhibitors (as described above), that is, agents to reduce or prevent hair growth. Hair growth inhibitors are preferably selected from the group consisting of activin, activin derivatives or activin agonists, ornithine decarboxylase inhibitors such as alpha-difluoromethylornithine or pentacyclic triterpenes such as ursolic acid, betulin, betulinic acid, oleanolic and its derivatives, 5alfareductase inhibitors, androgen receptor antagonists, Sadenosylmethionine decarboxylase inhibitors, gamma-glutamyl transpeptidase inhibitors, transglutaminase inhibitors, soy derived serine protease inhibitors, microorganism extracts, algae, different microalgae or plants and plants parts of plants, for example, from the families Leguminosae, Solanaceae, Graminae, Asclepiadaceae or Cucurbitaceae, the genera Chondrus, Gloiopeltis, Ceramium, Durvillea, Glycine max, Sanguisorba officinalis, Calendula officinalis, Hamamelis virginiana, Arnica montatumicum, Salnica montana, Salnica montana, Salix Gymnema sylvestre. Solutes
[0147] [00147] The formulations and products according to the present invention can also comprise one or more compatible solutes. Preferred compatible solutes are as described in WO 01/76572, particularly dimio-inositol phosphate (DIP), diglycerin phosphate (DGP), di-myo-inositol phosphate (DIP), 2.3 cyclic diphosphoglycerate (cDPG) , 1,1-di-glycerol phosphate (DGP), beta-mannosyl glycerate (firoin), beta-mannosyl glyceride (firoin-A) and di-mannosyl-di-inositol phosphate (DMIP) and ectoin and ectoin derivatives , as described in EP 0 553 884, EP 0 671 161 and WO 94/15923, in particular ((S) -1,4,5,6-tetrahydro-2-methyl-4-pyrimidinecarboxylic acid) and hydroxyectoin (( S, S) -1,4,5,6-tetrahydro-5-hydroxy-2-methyl-4-pyrimidinecarboxylic).
[0148] [00148] Preferably, the total amount of compatible solutes is in the range of 0.05 to 10% by weight, preferably 0.1 to 5% by weight, based on the total weight of the formulation or product. Solvents
[0149] [00149] The pharmaceutical compositions may contain such as, for example, aliphatic alcohols or 1,2-alkanedioles or of course simply water.
[0150] [00150] 1,2-Alcanodiols. Suitable 1,2-alkanedioles include 1,2-butadiol, 1,2-pentanediol, 1,2-hexanediol, 1,2-heptanediol, 1,2-octanediol, 1,2-nonanediol, 1,2-decanediol, 1,2-undecanediol, 1,2-dodecanediol and mixtures thereof. The preferred 1,2-alkanediol is 1,2-pentanediol.
[0151] [00151] Aliphatic alcohols. Suitable aliphatic alcohols are selected from the group consisting of ethanol, n-propanol, isopropyl alcohol, isomeric butanols and mixtures thereof. The preferred species is ethanol, in particular with a purity of at least 95%. Pigments
[0152] [00152] The cosmetic and / or pharmaceutical preparations according to the present invention advantageously, but not necessarily, comprise inorganic pigments based on finely dispersed metal oxides and / or other metal compounds that are insoluble or poorly soluble in water, in particularly oxides of titanium (TiO2), zinc (ZnO), iron (for example, Fe2O3), zirconium (ZrO2), silicon (SiO2), manganese (for example, MnO), aluminum (Al2O3), cerium (for example, Ce2O3), mixed oxides of the corresponding metals, and mixtures of such oxides. These pigments are amorphous to the X-ray or non-amorphous to the X-ray. X-ray amorphous oxide pigments are metallic oxides or semimetallic oxides that do not reveal or recognize any crystalline structure in X-ray diffraction experiments. Such pigments are often obtained by the reaction of flame, for example, by the reaction of a metal or semi-metal halide with hydrogen and air (or pure oxygen) in a flame.
[0153] [00153] In cosmetic and / or pharmaceutical preparations, x-ray amorphous oxide pigments are used as thickeners and thixotropic agents, flow aids for the stabilization of the emulsion and dispersion and as a carrier substance (for example, to increase the volume finely divided powders). X-ray amorphous oxide pigments that are known and frequently used in galenic cosmetic and dermatological preparations, for example, high purity silicon oxide. Preference is given to high purity X-ray amorphous silicon dioxide pigments with a particle size in the range of 5 to 40 nm and a surfactant area (BET) in the range of 50 to 400 m2 / g, preferably 150 at 300 m2 / g, where the particles should be considered as spherical particles of very uniform size. Macroscopically, silicon dioxide pigments are recognizable as loose white powders. Silicon dioxide pigments are sold commercially under the name Aerosil® (CAS-No. 7631-85-9) or Carb-O-Sil.
[0154] [00154] Advantageous Aerosil® grades are, for example, Aerosil® 0X50, Aerosil® 130, Aerosil® 150, Aerosil® 200, Aerosil® 300, Aerosil® 380, Aerosil®MQX 80, Aerosil® MOX 170, Aerosil®COK 84, Aerosil® R 202, Aerosil®R 805, Aerosil®R 812, Aerosil®R 972, Aerosil®R 974, Aerosil®R976.
[0155] [00155] According to the present invention, cosmetic and pharmacological preparations, preferably dermatological preparations, comprise from 0.1 to 20% by weight, advantageously from 0.5 to 10% by weight, more preferably from 1 to 5 % by weight of amorphous oxide pigments at X-ray.
[0156] [00156] Inorganic pigments not amorphous to X-ray are, according to the present invention, advantageously in hydrophobic form, that is, they have been treated on the surface to repel water. This surface treatment may involve providing the pigments with a thin hydrophobic layer through processes known per se. Such a process involves, for example, the production of the hydrophobic surface layer by a reaction according to n TiO2 + m (RO) 3Si-R '→ n TiO2 (surf.) where neither are stoichiometric parameters to be used as desirable, and R and R 'are desired organic radicals. Hydrophobic pigments prepared analogously to DE-A 33 14 742, for example, are advantageous.
[0157] [00157] The total amount of inorganic pigments, in particular hydrophobic inorganic micro pigments, in finished cosmetic and pharmacological preparations, in particular in dermatological preparations, is advantageously selected from the range of 0.1 to 30% by weight, preferably 0, 1 to 10.0% by weight, preferably 0.5 to 6.0% by weight, based on the total weight of the preparations. Ingredients for skin whitening
[0158] [00158] An additional content of ingredients for whitening the skin in cosmetic and pharmacological preparations, preferably dermatological preparations, is optional. Such skin lightening ingredients that can be used are, for example, but not limited to: kojic acid (5-hydroxy-2-hydroxymethyl-4-pyranone), kojic acid derivatives, such as, for example, dipalmitate kojic, arbutin, ascorbic acid, ascorbic acid derivatives, hydroquinone, hydroquinone derivatives, styryl resorcinol derivatives (e.g. 4- (1-phenylethyl) 1,3-benzenediol), sulfur-containing molecules such as glutathione or cysteine, for example, alpha-hydroxy acids (for example, citric acid, lactic acid, malic acid) and their derivatives, N-acetyl tyrosine and derivatives, undecenoylphenylalanine, gluconic acid, chromone derivatives such as aloesin, flavonoids, thymol derivatives, acid 1 -aminoethylphosphine, thiourea derivatives, ellagic acid, nicotinamide, zinc salts such as zinc chloride or zinc gluconate, for example, thujaplicin and derivatives, triterpenes such as malic acid, sterols such as ergosterol, benzofuranones tai s such as senquiunolide, vinyl and ethilguaiacol, dionic acids such as octodecenedioic acid and azelaic acid, inhibitors of nitrogen oxide synthesis such as L-nitroarginine and its derivatives, 2,7-dinitroindazole or thiocitruline, metal chelators (eg alpha-hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin, humic acid, gallic acid, bile extracts, bilirubin, biliverdin), retinoids, soy milk, soy extract, serine protease inhibitors or lipoic acid or other synthetic or natural active compounds skin and hair bleaching, these compounds are also being used in the form of a plant extract, such as bearberry extract, rice extract, papaya extract, licorice root extract or concentrated components from them, such as such as glabridine or licocalcona A, Artocarpus extract, extract of the species Rumex and Ramulus, extracts of the species of pine (Pinus) and extracts of the species Vitis or derivatives of stylbene concentrated from these, extract of saxifraga, blackberry, Scutelleria and / or grapes. Antioxidants
[0159] [00159] An additional content of antioxidants in cosmetic and pharmacological preparations, preferably dermatological preparations, is generally preferred. According to the present invention, favorable antioxidants that can be used are all the usual or suitable antioxidants for cosmetic and pharmacological preparations, preferably dermatological preparations. Antioxidants are advantageously selected from the group of amino acids (eg, glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (eg, urocanic acid) and their derivatives, peptides, such as D, L-carnosine, D-carnosine , L-carnosine and its derivatives (for example, anserine), carotenoids, carotenes (for example, αcarotene, β-carotene, lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its derivatives (for example, dihydrolipoic acid ), aurothioglycosis, propylthiouracil and other thiols (for example, thioredoxin, glutathione, cysteine, cystine, cystamine and glycosyl, Nacetyl, methyl, ethyl, propyl, amyl, butyl and lauryl, palmitoyl, oleyl, γlinoleyl, cholesteryl and its cholesterol and its cholesterol and its cholesterol and its cholesterol. glycerol) and their salts, dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and its derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and salts) and sulfoximine compounds (for example, sulfoximine butionin oximins, homocysteine sulfoximine, butionine sulfones, penta-, hexa-, heptathionine sulfoximine) at very low tolerated doses (eg pmol µmol / kg), and also chelating agents (metal) (eg α-hydroxy fatty acids , palmitic acid, phytic acid, lactoferrin), α-hydroxy acids (for example, citric acid, lactic acid, maleic acid), humic acid, bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and its derivatives, acids unsaturated fatty acids and their derivatives (eg γ-linolenic acid, linoleic acid, oleic acid), folic acid and its derivatives, ubiquinone and ubiquinol and their derivatives, vitamin C and derivatives (eg ascorbyl palmitate, ascorbyl Mg phosphate , ascorbyl acetate), tocopherols and derivatives (eg vitamin E acetate), vitamin A and derivatives (vitamin A palmitate), and benzoin resin coniferyl benzoate, rutinic acid and its derivatives, α-glycosylrutine, ferulic acid furfurilidenog lucitol, carnosine, butylhydroxy-toluene, butylhydroxyanisole, nordihydroguaiac acid, nordihydroguaiaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and its derivatives, zinc and its derivatives (eg ZnO, ZnSO4), selenium and its derivatives selenomethionine), stilbenes and their derivatives (for example, stilbene oxide, trans-stilbene oxide) and derivatives (salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids), acetophenone derivatives such as hydroxyacetophenone and their mixtures with phenoxyethanol and / or pentane 1,2-diol and / or hexane 1,2-diol and / or caprylyl 1,2-diol, are suitable according to the present invention.
[0160] [00160] The amount of the aforementioned antioxidants (one or more compounds) in the preparations is preferably between 0.001 to 30% by weight, more preferably from 0.05 to 20% by weight, and most preferably from 1 to 10% by weight , based on the total weight of the preparation. Vitamins
[0161] [00161] Preferred embodiments of cosmetic and pharmacological preparations, preferably the dermatological preparations of the invention, can also advantageously comprise vitamins and vitamin precursors, being possible for all vitamins and vitamin precursors that are suitable or customary for cosmetic and pharmacological preparations, especially dermatological preparations to be used. Those here that are worth mentioning are, in particular, vitamins and vitamin precursors, such as tocopherols, vitamin A, niacin and niacinamide acid, other B vitamins, in particular biotin, and vitamin C and panthenol and their derivatives, in particular panthenol esters and ethers, and cationically derived panthenols, such as panthenol triacetate, monoethyl panthenol ether and its cationic monoacetate and panthenol derivatives. If vitamin E and / or its derivatives represent antioxidants, it is advantageous to select their respective concentrations from the range of 0.001 to 10% by weight, based on the total weight of the formulation. If vitamin A or vitamin A derivatives, or carotenes or their derivatives represent antioxidants, it is advantageous to select their respective concentrations from the range of 0.001 to 10% by weight, based on the total weight of the formulation. Lipids
[0162] (i) parafinas saturadas lineares ou ramificadas (óleos minerais) tendo 15 ou mais átomos de C, em particular tendo de 18 a 45 átomos de C; (ii) ésteres tendo 12 ou mais átomos de C de ácidos graxos lineares ou ramificados tendo de 6 a 30 átomos de C e mono-, di- ou trióis lineares ou ramificados, saturados ou insaturados tendo de 3 a 30 átomos de C, estes ésteres não tendo nenhum grupo de hidroxila livre; (iii) ésteres de ácido benzoico e monoalcanóis lineares ou ramificados, saturados ou insaturados tendo de 8 a 20 átomos de C; (iv) monoésteres ou diésteres de álcoois tendo de 3 a 30 átomos de C e ácidos naftaleno-monocarboxílicos ou -dicarboxílicos; especialmente ésteres C6-C18 de ácido naftalenomonocarboxílico e ésteres di-C6-C18 de ácido naftalenodicarboxílico; (v) éteres di-C6-C18-alquílicos lineares ou ramificados, saturados ou insaturados; (vi) óleos de silicona; (vii) 2-alquila-1-alcanóis da fórmula (III)
[0163] [00163] Preferred embodiments of cosmetic and pharmacological preparations, especially of the dermatological preparations of the invention, comprise, if desired, other ingredients having treatment properties, such as, for example, fatty alcohols having from 6 to 30 C atoms. fatty alcohols here can be saturated or unsaturated and linear or branched. In addition, these fatty alcohols may in some cases be part of the oil (III) phase if they meet the definition given here. The alcohols that can be used are, for example, decanol, decenol, octanol, octenol, dodecanol, dodecenol, octadienol, decadienol, dodecadienol, oleyl alcohol, ricinoleyl alcohol, erucyl alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, capryl alcohol, caprylic alcohol, linoleyl alcohol, linolenyl alcohol and beenyl alcohol, and also Guerbet alcohols, such as, for example, 2-octyl-1-dodecanol, making it possible for the list to be extended practically as desirable for other alcohols of related structural chemistry. Fatty alcohols preferably originate from natural fatty acids and are conventionally prepared from the corresponding esters of fatty acids through reduction. The fatty alcohol fractions that are formed by reducing from naturally occurring fats and fatty oils, such as beef tallow, peanut oil, rapeseed oil, cottonseed oil, soybean oil, sunflower oil , palm seed oil, flaxseed oil, corn oil, castor oil, rapeseed oil, sesame oil, cocoa butter and coconut fat can also be used.
[0164] • ceramidas, onde as ceramidas são entendidas no sentido de Nacilesfingosinas (amidas de ácido graxo de esfingosina) ou análogos sintéticos de tais lipídios (as assim chamadas pseudoceramidas), que significativamente melhoram a capacidade de retenção de água do estrato córneo. • fosfolipídios, por exemplo, lecitina de soja, lecitina de ovo e cefalinas • ácidos graxos • fitoesteróis e gorduras ou ceras contendo fitoesterol • vaselina, óleos de parafina e óleos de silicona; estes últimos incluem, inter alia, dialquil- e alquilarilsiloxanos, tais como dimetilpolissiloxano e metilfenilpolissiloxano, e também seus derivados alcoxilados e quaternizados. [00164] Substances having treatment properties that can advantageously be used in cosmetic and pharmacological preparations, especially dermatological preparations, may also include • ceramides, where ceramides are understood to mean Nacilesphingosines (sphingosine fatty acid amides) or synthetic analogs of such lipids (so-called pseudoceramides), which significantly improve the water-holding capacity of the stratum corneum. • phospholipids, for example, soy lecithin, egg lecithin and cephalins • fatty acids • phytosterols and fats or waxes containing phytosterols • petroleum jelly, paraffin oils and silicone oils; the latter include, inter alia, dialkyl- and alkylarylsiloxanes, such as dimethylpolysiloxane and methylphenylpolysiloxane, as well as their alkoxylated and quaternized derivatives.
[0165] [00165] The aqueous phase of the preparations according to the present invention optionally advantageously comprises alcohols, diols or polyols (lower alkyl), and their ethers, preferably ethanol, isopropanol, propylene glycol, 1,2-pentanediol, 1, 2-hexanediol, 1,2-octanediol, 1,2-decanediol, a mixture of 1,2-hexanediol and 1,2-octanediol, a mixture of 1,2-hexanediol and 1,2-decanediol, a mixture of 1 , 2-octanediol and 1,2-decanediol, a mixture of 1,2-hexanediol, 1,2-octanediol and 1,2-decanediol, glycerin, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl ether, - monoethyl or monobutyl ether diethylene glycol monomethyl or - monoethyl and similar products, and also alcohols (lower alkyl), for example, ethanol, 1,2-propanediol, glycerol, and, in particular, one or more thickeners that can be advantageously selected from the group of silicon dioxide, aluminum silicates, polysaccharides and their derivatives, for example, hyal acid uronic, xanthan gum, hydroxypropylmethylcellulose, particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbomers, for example, but not limited to, Carbopol® categories 980, 981, 1382, 2984 , 5984, in each case individually or in combination. Anti-inflammatory compounds
[0166] [00166] Preferred embodiments of cosmetic and pharmaceutical preparations, especially the dermatological preparations of the invention, may also comprise active anti-inflammatory compounds and / or relief from redness and / or itching (anti-irritants). All active anti-inflammatory or redness and / or itch-relieving compounds that are suitable or customary for cosmetic, dermatological and pharmacological preparations can be used here. The active anti-inflammatory or redness and / or itch-relieving compounds that are advantageously employed are steroidal anti-inflammatory substances of the corticosteroid type, such as hydrocortisone, dexamethasone, dexamethasone phosphate, methylprednisolone or cortisone, making it possible for the list to be extended through the addition of other steroidal anti-inflammatory drugs. Nonsteroidal anti-inflammatory drugs can also be used. Those that will be mentioned here by way of example are oxicans, such as piroxicam or tenoxicam; salicylates, such as aspirin, Disalcid, Solprin or fendosal; acetic acid derivatives, such as diclofenac, fenclofenac, indomethacin, sulindac, tolmetin or clindanac; fenmatomates, such as derivatives of mefenamic, meclofenamic, flufenamic or niflumic acid; propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen or pyrazoles, such as phenylbutazone, oxyphenylbutazone, febrazone or azapropazone.
[0167] [00167] Alternatively, anti-inflammatory substances or relief from redness and / or itchiness can be used. Plant extracts, highly active specific fractions of plant extract and highly pure active substances isolated from plant extracts can be used. Extracts, fractions and active substances of chamomile, aloe vera, species Commiphora, species Rubia, willow, rose-bay, willow, oats, and also pure substances, such as, inter alia, bisabolol, apigenin 7-glycoside, boswellic acid, phytosterols , glycyrrhizic acid, glabridine or lycocalcone A, are particularly preferred. The preparations of the present invention can also comprise mixtures of two or more active anti-inflammatory compounds. Bisabolol, boswellic acid, as well as highly pure isolated extracts and active compounds from oats and Echinacea are particularly preferred for use in the context of the invention as anti-inflammatory substances and relief from redness and / or itching, and alpha-bisabolol and extracts and the highly pure active compounds isolated from oats are especially preferred.
[0168] [00168] The amount of anti-irritants (one or more compounds) in the preparations is preferably between 0.0001% and 20% by weight, with a particular preference of 0.0001% to 10% by weight, in particular from 0.001% to 5% by weight, based on the total weight of the preparation. Humidity regulator
[0169] [00169] Preferred embodiments of cosmetic and pharmacological preparations, especially the dermatological preparations of the invention, may advantageously also comprise regulators of moisture retention. The following substances, for example, are used as moisture retention regulators (humectants): sodium lactate, urea, alcohols, glycerol, sorbitol, propylene glycol, 1,2-aliphatic diols with a C number from 5 to 10, collagen, elastin or hyaluronic acid, diacila adipates, petrolatum, ectoin, urocanic acid, lecithin, panthenol, phytanthriol, lycopene, algae extract, ceramides, cholesterol, glycolipids, chitosan, chondroitin sulfate, polyamino acids and polyamine amino acids, lanolin, lanolin esters, amino acids, alpha-hydroxy acids (for example, citric acid, lactic acid, malic acid) and their derivatives, sugars (for example, inositol), alpha-hydroxy fatty acids, phytosterols, triterpene acids, such such as betulinic acid or ursolic acid, seaweed extracts. Plant extracts
[0170] [00170] The preferred modalities of cosmetic and pharmacological preparations, especially the dermatological preparations of the invention, can also advantageously comprise plant extracts, which are conventionally prepared by extracting the entire plant, but also in individual cases exclusively of the flower and / or leaves, wood, bark or roots of the plant. With regard to the plant extracts that can be used, reference is made in particular to the extracts that are listed in the table beginning on page 44 of the third edition of the Leitfaden zur Inhaltsstoffdeklaration kosmetischer Mittel [Manual of Declaration of the Constituents of Cosmetic Compositions], published by Industrieverband Körperpflegemittel und Waschmittel eV (IKW), Frankfurt. The extracts that are particularly advantageous are those of aloe, witch hazel, algae, oak bark, rose-bay willow, nettle, dead nettle, hops, chamomile, raw corn, arnica, marigold, burdock root, horsetail, hawthorn , linden blossom, almond, pine, chestnut, sandalwood, juniper, coconut, mango, apricot, orange, lemon, lime, grapefruit, apple, green tea, grapefruit seed, wheat, oats, barley, sage, thyme, wild thyme, rosemary, birch, mallow, lady's blouse, willow bark, restocker, coltsfoot, hibiscus, ginseng and ginger.
[0171] [00171] In this context, extracts of aloe vera, chamomile, algae, rosemary, marigold, ginseng, cucumber, sage, nettle, linden flower, arnica and witch hazel are especially preferred. Mixtures of two or more plant extracts can also be used. The extraction agents that can be used for the preparation of the mentioned plant extracts are, inter alia, water, alcohols and mixtures thereof. In this context, among alcohols, lower alcohols such as ethanol and isopropanol, but also polyhydric alcohols, such as ethylene glycol, polypropylene glycol and butylene glycol, are preferable, and in particular both as the single extracting agent and in mixtures with Water. Vegetable extracts can be used in both pure and diluted form. ILLUSTRATION OF THE INVENTION THROUGH FIGURES 1 TO 4
[0172] [00172] The present invention is explained in more detail by the following working examples, but also by Figures 1 to 4:
[0173] [00173] Figure 1: Photographs of residual whitening on the skin after the application of 2.5 mg / cm2 of commercial vs. sun protection formulations. a formulation produced in the laboratory containing 4% of a titanium dioxide coated with cetearyl nonoanoate, according to the invention, which were rubbed into the skin for 15 seconds.
[0174] [00174] Figure 2: Photographs of residual whitening on the skin after the application of 2.5 mg / cm2 of lotions each containing 4% of the main commercially available categories of titanium dioxide used for cosmetic, dermatological and pharmacological preparations for protection of human skin against the harmful effects of UV radiation vs. a formulation produced in the laboratory containing 4% of a titanium dioxide coated with cetearyl nonoanoate, according to the invention, which were rubbed into the skin for 15 seconds.
[0175] [00175] Figure 3: Photographs of residual whitening on the skin after the application of 2.5 mg / cm2 of sprays, each containing 4% of the main commercially available categories of titanium dioxide used for cosmetic, dermatological and pharmacological preparations for the protection of human skin against the harmful effects of UV radiation vs. a formulation produced in the laboratory containing 4% of a titanium dioxide coated with cetearyl nonoanoate, according to the invention, which were rubbed into the skin for 15 seconds.
[0176] [00176] Figure 4: Photographs of residual bleaching on the skin after the application of 2.5 mg / cm2 of lotions that were rubbed into the skin for 15 seconds, one containing 4% titanium dioxide coated with cetearyl nonoanoate, according to with the invention, the other containing the same category of titanium dioxide, but without the cetearyl nonanoate coating, in which 4% cetearyl nonanoate was added to the lotion separately. EXAMPLES COMPARATIVE EXAMPLES Residual skin whitening after product application
[0177] [00177] To illustrate the extent of residual bleaching left by formulations containing nano-degrees of titanium dioxide on human skin, we apply 2.5 mg / cm2 of the main commercially available sunscreens to the volar forearm covering a surface area of 18 square centimeters and rubbed into the skin with a finger using the same pressure and speed for 15 seconds. The photographs were taken to show the residual whiteness of the formulation left on the skin's surface vs. a laboratory-produced formulation containing 4% titanium dioxide coated with cetearyl nonanoate. Since the ingredients of cosmetic formulations had to be listed on the finished product label, in descending order by weight by law in many countries, an experienced formulator can estimate approximately the percentage by weight of the ingredient that is present in the formulation.
[0178] [00178] The photographs in figure 1 show that the formulation with 4% titanium dioxide coated with cetearyl nonanoate had significantly less residual bleaching on the skin than the commercially available formulations, which are estimated to contain from 1 to 2% or 3 to 4% nano titanium dioxide, respectively.
[0179] [00179] To have a more direct comparison in discounting formulation variability as a reason for residual bleaching, we prepare formulations in which all ingredients are identical, except the degree of nano titanium dioxide used in a single variable study with the main categories commercially available titanium dioxide used in cosmetic, dermatological and cosmetic, pharmacological preparations for the protection of human skin against the harmful effects of UV radiation. Two common types of formulation were chosen for a lotion and a spray. EXAMPLES ACCORDING TO THE INVENTION Example 1 Sun protection lotion (OW), SPF expected 30
[0180] [00180] Prepare phase A without Keltrol, TiO2 and heat to 85 ° C. Add TiO2 and Keltrol and mix for a short time with an Ultra Turrax®. Prepare phase B and heat to 85 ° C until homogeneous. Add phase B to phase A without stirring. Cool with agitation to 60 ° C, then homogenize with Ultra Turrax. Add Phase C and cool to room T with stirring until homogeneous and then homogenize for a short time with an Ultra Turrax®. Check the pH, adjust to 6.5 if necessary.
[0181] [00181] The photographs in Figure 2 show that the formulation with titanium dioxide coated with cetearyl nonanoate (A) had significantly less residual bleaching on the skin than formulations produced with commercially available categories of titanium dioxide, except for the product competitive C, but this formula was tastier and had a much rougher skin feel than formula A. Examples of formulation are given in Table 1.
[0182] [00182] Prepare phase A without TiO2, Pemulen and heat to 50 ° C. Add TiO2 and Pemulen, mix for 30s with an Ultra Turrax®. Add phase B ingredients together and add to phase A without stirring, then homogenize with Ultra Turrax®. Then phase C at room temperature with gentle agitation. The pH should be 6.5.
[0183] [00183] The photographs in Figure 3 show that the formulation with titanium dioxide coated with cetearyl nonanoate (A) had significantly less residual bleaching on the skin than formulations B, D and E produced with commercially available categories of titanium dioxide , and although formulation C produced with the commercially available category of titanium dioxide has a reduced bleaching similar to formula A, but it is much brighter and has a much rougher feel on the skin than A. It is known that nonanoate of cetearyl, when added as a separating ingredient to emulsions containing titanium dioxide, reduces whitening on the skin to some extent (Symrise technical bulletin - SymMollient® S Quick Sheet). To show that titanium dioxide coated with cetearyl nonoate has a reduced whitening effect compared to non-cetearyl titanium dioxide, an emulsion was prepared with 4% titanium dioxide plus 4% cetearyl nonanoate added separately and a emulsion with 4% of the same category of titanium dioxide that was coated with cetearyl nonanoate. Formulation examples are provided in Table 2.
[0184] [00184] Prepare phase A without Keltrol, TiO2 and heat to 85 ° C. Add TiO2 and Keltrol and mix for a short time with an Ultra Turrax®. Prepare phase B and heat to 85 ° C until homogeneous. Add phase B to phase A without stirring. Cool with agitation to 60 ° C, then homogenize with Ultra Turrax. Add Phase C and cool to room T with stirring until homogeneous and then homogenize for a short time with an Ultra Turrax®. Check the pH, adjust to 6.5 if necessary.
[0185] [00185] The photographs in Figure 4 show that the formulation with titanium dioxide coated with cetearyl nonanoate (A) had significantly less residual bleaching on the skin than formulations produced with separately added cetearyl nonoate (B). Formulation examples are provided in Table 3.

FORMULATION EXAMPLES Example 4 Sun protection lotion (O / W), SPF expected 50+ Manufacturing: Phase A: Heat up to approx. 85 ° C without Ke ltrol® and Titanium dioxide, when all ingredients are dissolved, add Keltrol® and Titanium dioxide and mix with an Ultra Turrax® for a short period of time. Phase B: First add the water then add the neutralizing agent Biotive® L-Arginine and the sodium hydroxide solution. Shake until smooth. Add Neo Heliopan® Hidroand, stir until everything is dissolved. Add the rest of the ingredients without Dragocolor to phase B and heat to approx. 80 ° C, add Dragocolor and homogenize for a short period of time, then add the hot phase B in the hot phase A and start homogenization with an Ultra Turrax® ( 13000 rpm / 1 minute per 100 g of emulsion). Cool to room temperature while stirring. Phase C: Add phase C and stir until homogeneous. The composition is provided in Table 4.


Example 5 Sun protection lotion (O / W), expected SPF 50 Phase A: Mix the components without Keltrol® and TiO2 and heat to approx. 85 ° C. Add Keltrol® and TiO2 and mix for a short time, approx. 0.5 min. with an Ultra Turrax® T25. Phase B: Mix the components while heating to 80 ° C until a clear solution is obtained. Add phase B water without stirring to heat phase A oil. Stir until cool to 60 ° C, then start homogenization with an Ultra Turrax®. Cool while stirring. Phase C: Add the ingredients of Phase C while stirring to phase A / B at room temperature. Homogenize with an Ultra Turrax® for a short period of time. The composition is provided in Table 5.


Example 6 Sun protection balm (O / W), expected SPF 50 Phase A: Mix phase A without SymSave, Keltrol® and NaOH with an Ultra Turrax. Start stirring with a vane shaker, then add Keltrol and SymSave and stir until a homogeneous cloudy solution is obtained. Add NaOH while stirring completely until the solution becomes a clear gel. Phase B: Mix the ingredients without TiO2 while heating to 60 ° C until a clear solution is obtained. Add TiO2 and mix for a short period of time. Add phase B slowly with stirring in phase A water. Cool while stirring. Phase C: Add the ingredients of Phase C while stirring to phase A / B at room temperature. Start homogenization with an Ultra Turrax® until a homogeneous balm is obtained. The composition is provided in Table 6.

Example 7 Anti-aging sunscreen lotion (O / W), SPF expected 30 Phase A: Mix the components without TiO2 and Keltrol® T in approx. 85 ° C, then add TiO2 and Keltrol® T. Homogenize air for a short time with an Ultra Turrax®. Phase B: Mix the components and heat to approx. 80 ° C until dissolved. Add phase B to phase A while stirring. Cool while stirring to 60 ° C and mix with an Ultra Turrax®. After cooling to room temperature while stirring. Phase C: Add all the ingredients gradually and stir until homogeneous. Check the pH value. The pH value should be approx. 6.4. If the pH value is correct, mix with an Ultra Turrax®. The composition is provided in Table 7.

Example 8 Low viscosity (O / W) sunscreen lotion, SPF expected 50+ Phase A: Mix the ingredients without titanium dioxide, Keltrol® and Pemulen® and heat up to approx. 85 ° C. When all the ingredients are dissolved add titanium dioxide, Keltrol® and Pemulen® and mix with an Ultra Turrax® T25 for a short period of time (30 seconds). Phase B: Mix the ingredients and heat up to approx. 80 ° C. Add phase B to phase A and mix with an Ultra Turrax® (13000 rpm / 1 minute per 100 g of emulsion) at 60 ° C. Cool to room temperature while stirring. Phase C: Add to phase A / B with agitation until homogeneous. Phase D: Add to phases A / B / C while stirring. Homogenize with an Ultra Turrax (13000 rpm / 1 minute per 100 g of emulsion). The composition is provided in Table 8.

Example 9 Children's sun protection cream (O / W) without organic UV filters, SPF expected 30 Phase A: Heat to approx. 85 ° C without Keltrol® CG-T and titanium dioxide. Add Keltrol® CG-T and titanium dioxide and then mix. Part B: Heat to 80 to 85 ° C with stirring, then add part B to part A with stirring and then mix. Part C: Mix phase C with stirring. Then add in parts A / B around 60 ° C with agitation until homogeneous. Allow to cool to room temperature and then add phase D with stirring, then homogenize. The composition is provided in Table 9.

Example 10 Expected SPF 50 sunscreen spray Phase A: Mix the ingredients without Pemulen® TR2 at approx 60 ° C with stirring. Add Pemlen® TR2 and mix for a short period of time, approx. 0.5 min. with an Ultra Turrax® T25. Phase B: Dissolve ExpertGel® in water while stirring. When dissolved, add neutralizing agents and Neo Heliopan® Hydro. When dissolved add the rest of the ingredients and stir until a clear solution is obtained. Heat slightly if necessary to solubilize SymSave® H. Add water in phase B without stirring to the hot oil in phase A. Homogenize with an Ultra Turrax® for approximately 5 min. Shake to cool. Phase C: Mix the ingredients by stirring and then in phase A / B. Cool while stirring. Phase D: Add them separately in phases A / B / C with stirring at room temperature. Then mix for a short period of time. The composition is provided in Table 10.

Example 11 Broad spectrum of water resistance O / W SPF expected 50+ Phase A: Heat all components except Xanthan gum and TiO2 to 85 ° C. Then add xanthan gum and TiO 2 and mix. Phase B: Heat all components to 85 ° C and add to Part A with stirring, stir to room temperature. Phase C: Add Part C to Parts A and B and mix. The composition is provided in Table 11.
Example 12 Sun protection lotion with tanning accelerator, SPF expected 30 Phase A: Mix the ingredients in approx. 85 ° C if Keltrol®, Aristoflex® and titanium dioxide, when all ingredients are dissolved, add Keltrol®, Aristoflex® and Titanium dioxide and mix with an Ultra Turrax® for a short period of time. Part B: Mix the ingredients with agitation at approximately 80 ° C. Add the hot phase B to the hot phase A, cool with agitation to 60 ° C and start homogenization with an Ultra Turra x®. Cool to room temperature while stirring. Part C: Add the ingredients in parts A / B as listed with agitation and allow to cool to room temperature. Part D: Add the ingredients with agitation and mix for a short period of time. The composition is provided in Table 12.

Example 13 CC cream with expected SPF 30 Phase A: Mix the ingredients in approx. 85 ° C if Keltrol®, Aristoflex® and titanium dioxide, when all ingredients are dissolved, add Keltrol®, Aristoflex® and Titanium dioxide and mix with an Ultra Turrax® for a short period of time. Phase B: Add water and Biotive® L-Arginine neutralizing agents and sodium hydroxide solution and stir until homogeneous. Then add Neo Heliopan® Hydro and stir until everything has dissolved. Add the rest of the ingredients without Dragocolor® to phase B and heat to approx. 80 ° C, add Dragocolor® and mix for a short period of time, then add hot phase B to hot phase A and start homogenization with an Ultra Turrax® ( 13000 rpm / 1 minute per 100 g of emulsion). Cool to room temperature while stirring. Part C: Add the ingredients in parts A / B as listed with agitation and allow to cool to room temperature. Part D: Add the ingredients with agitation and mix for a short period of time. The composition is provided in Table 13.

Example 14 Sunscreen sticks with SPFs expected from (A) 30 and (B) 50+ Phase A: Mix the ingredients and heat with agitation to approx. 80 ° C. Keep the temperature. Phase B: Mix the ingredients then add phase B to phase A and mix. Keep the temperature. Shake slightly to allow the closed air to escape from the mass. Transfer to the rod holders at 75 to 80 ° C. Two compositions are provided in Table 14.

Example 15 Sun protection cream (W / O), expected SPF 50, water resistant Part A: Mix the ingredients with stirring at around 85 ° C. Part B: Mix the ingredients with stirring at around 85 ° C, then add A. Allow to cool with stirring then homogenize. Part C: Stir at room temperature. The composition is provided in Table 15.

Example 16 O / W emulsions, SPF> 20










Example 17 Emulsions W / O, SPF> 20






Example 18 Spray / mousse emulsions, SPF> 20







Example 19 Daily Protection Preparations

权利要求:
Claims (15)
[0001]
Coated titanium dioxide particles, characterized by the fact that at least one coating layer comprises an ester produced from a mixture of fatty alcohol and C6 to C12 aliphatic acids as the coating material.
[0002]
Coated titanium dioxide particles according to claim 1, characterized in that the coating material is at least one derivative of C16 - C18 nonanoate or a mixture thereof.
[0003]
Coated titanium dioxide particles according to claim 1 or 2, characterized in that the coating material comprises cetearyl nonanoate and / or cetearyl isononoate.
[0004]
Coated titanium dioxide particles according to any one of claims 1 to 3, characterized in that the titanium dioxide particles comprise one or more additional coating layers, whereby the coating material is selected from the group consisting of on silica (SiO2), aluminum hydroxide (Al2 (OH) 3, aluminum oxide (Al2O3), alumina, sodium hexametaphosphate (Na (PO3) 6), sodium metaphosphate (Na (PO3) n, aluminum stearate, stearic acid, lauric acid, dimethylpolysiloxane, dimethicone, methyl polysiloxane, simethicone, or mixtures thereof.
[0005]
Titanium dioxide particles coated according to any one of claims 1 to 4, characterized in that the loading capacity of the coating material comprises a mixture of a fatty acid ester, in the particles is in the range of 5 to 25 %, referring to the total weight of a particle.
[0006]
Titanium dioxide particles coated according to claim 4 or 5, characterized in that the load capacity of the additional coating material is in the range of 5 to 15% by weight, referring to the total weight of a particle.
[0007]
Coated titanium dioxide particles according to any one of claims 1 to 5, characterized by the fact that at least one dimension of the individual crystals that make up the particle clusters is <100 nm.
[0008]
Cosmetic and / or pharmaceutical preparations, characterized in that they comprise coated titanium dioxide particles as defined in claims 1 to 6.
[0009]
Cosmetic and / or pharmaceutical preparations according to claim 8, characterized by the fact that the amount of titanium dioxide particles is in the range of 0.5 to 25%, referring to the total preparation.
[0010]
Cosmetic and / or pharmaceutical preparations according to claim 8 or 9, characterized by the fact that the preparations still comprise at least one UV filter in an amount from 0.1 to 65.0%, referring to the total amount of all UV filters, referring to the total amount of the preparation.
[0011]
Cosmetic and / or pharmaceutical preparations according to claim 8, characterized by the fact that UV filters are selected from the group consisting of: - Avobenzone - Homosalate - Octisalate - Octocylene - 2-ethylhexyl p-methoxycinnamate - isoamyl p-methoxycinnamate - 3- (4'-methylbenzylidene) -d, l-camphor - 2,4,6-trianilino (p-carbo-2'-ethylexil-1'-oxy) -1,3,5-triazine - Tris-biphenyl triazine - Diethylexil Butamido Triazone - Benzylidenomalonate-polysiloxane - 2-ethylexyl 4-dimethylaminobenzoate - Drometrizole trisiloxane - Bis-Ethylexyloxyphenol methoxyphenyl triazine - 2,2'-methylenebis (6- (2H-benztriazol-2-yl) -4-1,1,3,3-tetramethylbutyl) -phenol), - Diethylamino hydroxybenzoyl Hexyl Benzoate - Disodium phenyl-dibenzimidazole tetrasulfonate and its salts - Phenylbenzimidazole sulfonic acid and its salts - Terephthalene sulphonic acid and its salts - Benzophenone-4 and its salts - Benzophenone-3 - Menthyl anthranilate - Padimato O - Zinc oxide and their mixtures.
[0012]
Cosmetic and / or pharmaceutical preparations according to any one of claims 8 to 11, characterized in that the cosmetic or pharmaceutical preparations comprise other auxiliaries and additives selected from surfactants, oily bodies, emulsifiers, coemulsifiers, super-greasing agents, pearlization waxes , consistency factors, polymers, silicone compounds, waxes, stabilizers, anti-dandruff agents, film-forming agents, swelling agents, hydrotropes, preservatives, solubilizers, complexing agents, reducing agents, alkalizing agents, perfume oils, dyes, thickeners, fats , lecithins, phospholipids, humectants, biogenic agents, antioxidants, deodorants, antiperspirants, insect repellents, self-tanning agents, tyrosine inhibitors (depigmentation agents), embedding agents, biogenic active ingredients, antimicrobial agents, antifoams, pigments that have a col action prayer, aqueous and non-aqueous plant extracts, and others as additional auxiliaries and additives.
[0013]
Cosmetic and / or pharmaceutical preparations according to any of claims 8 to 12, characterized in that the cosmetic or pharmaceutical preparations have a sun protection factor of at least 2.
[0014]
Cosmetic and / or pharmaceutical preparations according to any of claims 8 to 13, characterized by the fact that the UVA protection factor is at least 2, measured by Colipa Method for the in vitro determination of UVA protection, 2011 or the strictly related ISO standard ISO 24443-2012 Determination of UVA photoprotection of sunscreen in vitro.
[0015]
Cosmetic and / or pharmaceutical preparations according to any of claims 8 to 14, characterized by the fact that cosmetic or pharmaceutical preparations are a dermatological preparation, selected from the group consisting of creams, gels, hydrogels, gels, hydrodispersion gels, oil gels, lotions, balms.

类似技术:

---

公开号 | 公开日 | 专利标题

---

BR102015005868B1|2021-01-26|titanium dioxide coated to reduce the bleaching effect on the skin

---

US20190247322A1|2019-08-15|Active Mixture of 1,2-hexanediol and 1,2-octanediol

---

US9889078B2|2018-02-13|Skin and/or hair whitening mixture

---

US9125936B2|2015-09-08|Ginger extract for the protection of stem cells

---

EP2939710B1|2020-06-17|Active Mixtures

---

US20200397677A1|2020-12-24|Cosmetic compositions

---

BR112015002651B1|2019-08-27|cosmetic compositions

---

US20180153783A1|2018-06-07|Cosmetic compositions

---

US9498424B2|2016-11-22|Active mixtures of acylated oligopeptides and troxerutin

---

US20180185301A1|2018-07-05|Pharmaceutical compositions comprising polyalkylene glycol derivatives

---

BR112018074006B1|2021-06-15|MIXTURE FOR HAIR CARE, ITS USE, COMPOSITION AND METHOD FOR HAIR OR PERSONAL CARE

---

US10391071B2|2019-08-27|Compositions comprising valerian extracts

---

BR112018007384B1|2021-02-17|composition obtained by spray drying, cosmetic preparation, skin care composition and use of one or more carrier materials

---

BR112020003545A2|2020-09-01|use of extracts of isochrysis sp

---

US20160250121A1|2016-09-01|Use of mono ornithine ketoglutarate |

同族专利:

---

公开号 | 公开日

---

KR102368163B1|2022-02-25|

---

EP2921157A1|2015-09-23|

---

EP2921157B1|2017-08-16|

---

ES2643590T3|2017-11-23|

---

CN104921965A|2015-09-23|

---

US20150265510A1|2015-09-24|

---

US9517190B2|2016-12-13|

---

JP6374206B2|2018-08-15|

---

CN104921965B|2019-09-20|

---

JP2015178437A|2015-10-08|

---

BR102015005868A2|2016-03-29|

---

WO2015139782A1|2015-09-24|

---

KR20150108796A|2015-09-30|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

---

US2653899A|1952-04-14|1953-09-29|Lilly Co Eli|Erythromycin, its salts, and method of preparation|

---

US2944061A|1957-09-20|1960-07-05|Acyl derivatives and process |

---

US3053865A|1958-03-19|1962-09-11|Merck & Co Inc|Novel 16-alkyl and 16-alkylene steroids and processes|

---

FR3124M|1961-02-02|Boots Pure Drug Co Ltd|

---

US3558690A|1965-04-08|1971-01-26|Gelgy Chemical Corp|Substituted derivatives of 2-anilinophenylacetic acids and a process of preparation|

---

FR1546478A|1967-01-27|1968-11-22|Rhone Poulenc Sa|New derivatives of 3-benzoylphenylacetic acid and their preparation|

---

US3883545A|1968-08-31|1975-05-13|Hoechst Ag|Certain 1-hydroxy-2-pyridones|

---

GB1288581A|1969-01-14|1972-09-13|

---

US4150052A|1971-02-04|1979-04-17|Wilkinson Sword Limited|N-substituted paramenthane carboxamides|

---

US4199574A|1974-09-02|1980-04-22|Burroughs Wellcome Co.|Methods and compositions for treating viral infections and guanine acyclic nucleosides|

---

JPS5842167B2|1977-04-01|1983-09-17|Shiseido Co Ltd|

---

AT10272T|1979-08-22|1984-11-15|Sandoz Ag|PROPENYLAMINE, METHOD FOR THE PRODUCTION THEREOF, PHARMACEUTICAL COMPOSITIONS CONTAINING IT AND THEIR USE AS MEDICINAL PRODUCTS.|

---

DE3314742C2|1983-04-23|1987-04-02|Degussa Ag, 6000 Frankfurt, De|

---

IL73534A|1983-11-18|1990-12-23|Riker Laboratories Inc|1h-imidazoquinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds|

---

US5028417A|1987-07-20|1991-07-02|Johnson & Johnson Consumer Products, Inc.|Sunscreen compositions|

---

IL100810A|1992-01-30|1996-12-05|Yeda Res & Dev|Pharmaceutical compositions comprising 2-methyl-4-carboxy-5-hydroxy-tetrahydropyrimidine and/or 2-methyl-4-carboxy-tetrahydropyrimidine methods for the isolation and purification of said compounds and substantially pure 2-methyl-4-carboxy-5-hydroxy-3, 4, 5, 6-tetrahydropyrimidine salts 5-ethers and 5-esters thereof|

---

DE4244580A1|1992-12-31|1994-07-07|Galinski Erwin A|Process for the in vivo extraction of ingredients from cells|

---

JP3220305B2|1993-09-30|2001-10-22|花王株式会社|UV protection composition|

---

DE4342560A1|1993-12-14|1995-06-22|Marbert Gmbh|Use of 1,4,5,6-tetra:hydro-4-pyrimidine carboxylic acid derivs. in cosmetics|

---

JPH10251123A|1997-03-11|1998-09-22|Kose Corp|Surface-treated titanium oxide powder and cosmetic containing the powder|

---

US6159480A|1997-12-15|2000-12-12|Neostrata Company, Inc.|Cosmetic makeup composition|

---

DE50104611D1|2000-04-12|2004-12-30|Bitop Ag|USE OF COMPATIBLE SOLUTES AS SUBSTANCES WITH RADICAL-CATCHING PROPERTIES|

---

US6942878B2|2000-09-11|2005-09-13|Showa Denko K.K.|Cosmetic composition|

---

JP3524502B2|2000-12-11|2004-05-10|カネボウ株式会社|Cosmetics|

---

JP3589987B2|2001-01-25|2004-11-17|カネボウ株式会社|Agar-coated powder, method for producing the same, and cosmetic comprising the powder|

---

GB0221697D0|2002-09-18|2002-10-30|Unilever Plc|Novel compouds and their uses|

---

ES2342466T7|2003-11-21|2012-11-19|Givaudan Sa|P-MENTANOCARBOXAMIDS N-SUBSTITUTED.|

---

JP4176055B2|2004-06-24|2008-11-05|株式会社カネボウ化粧品|Cosmetics|

---

JP2007039362A|2005-08-02|2007-02-15|Pola Chem Ind Inc|Slurry for production and external preparation for skin, containing the same|

---

JP2009518329A|2005-12-09|2009-05-07|ディーエスエムアイピーアセッツビー．ブイ．|Novel cosmetic or dermatological composition comprising modified titanium dioxide particles|

---

EP2033688B1|2007-08-20|2012-10-17|Symrise AG|Oxalic acid derivatives and their use as physiological cooling agents|

---

US8623386B2|2008-04-11|2014-01-07|Kobo Products, Inc.|Natural ester, wax or oil treated pigment, process for production thereof, and cosmetic made therewith|

---

JP2012121810A|2009-02-26|2012-06-28|Tayca Corp|Organic compound composite powder having ultraviolet absorbing ability, method for producing the same, and cosmetic preparation containing the same|

---

GB0922552D0|2009-12-23|2010-02-10|Croda Int Plc|Particulate titanium dioxide|

---

FR2971706B1|2011-02-18|2013-02-15|Oreal|COMPOSITION CONTAINING FILTERANT COMPOSITE PARTICLES AND MODIFIED HYDROPHOBIC INORGANIC FILTER PARTICLES USING NATURALLY OIL OR WAX|

---

JP5973205B2|2012-03-30|2016-08-23|株式会社コーセー|Processed powder for cosmetics and cosmetics containing the same|

---

US8545891B1|2012-12-28|2013-10-01|L'oreal|Sunscreen compositions having synergistic combination of titanium dioxide filters|FR3021530B1|2014-05-28|2016-07-08|Oreal|OIL-IN-WATER EMULSION SOLAR PROTECTION COMPOSITION COMPRISING AT LEAST ONE MIXTURE OF SURFACTANTS|

---

EP3226829B1|2014-12-02|2018-02-28|Unilever NV|A personal care cream composition|

---

US10617627B2|2015-02-26|2020-04-14|Edgewell Personal Care Brands, Llc|Robust sunscreen compositions|

---

US10370540B2|2015-09-11|2019-08-06|Tronox Llc|Inorganic pigments surface treated with polyol esters|

---

FR3046063B1|2015-12-23|2019-05-10|L'oreal|PHOTOPROTECTIVE COSMETIC COMPOSITION AND PROCESS FOR PREPARING THE SAME|

---

FR3046156B1|2015-12-28|2019-12-13|Sumitomo Osaka Cement Co., Ltd|METAL OXIDE POWDER, DISPERSION LIQUID AND COSMETIC MATERIAL|

---

CN107157789A|2016-02-29|2017-09-15|爱茉莉太平洋股份有限公司|Isolate harm ray make-up composition|

---

KR101833612B1|2016-03-30|2018-02-28|선진뷰티사이언스|Polymer composite particles containing much of organic sunscreen agents and the method for preparing thereof|

---

ES2590229B8|2016-06-29|2020-06-24|Marketing Tecnico Sanitario S L|PROCEDURE FOR THE PREPARATION OF A VENOPROTECTING CREAM WITH SUN PROTECTOR AND COMPOSITIONS OBTAINED BY THIS PROCEDURE|

---

JPWO2018062469A1|2016-09-29|2019-07-11|ロート製薬株式会社|Skin external composition|

---

DE102017201948A1|2017-02-08|2018-08-09|Beiersdorf Ag|Sensory attractive hydrodispersion with UV protection filters|

---

JP2018145117A|2017-03-02|2018-09-20|株式会社 資生堂|Oil-in-water emulsion sunscreen cosmetics|

---

IT201700078091A1|2017-07-11|2019-01-11|Biokosmes Srl|NEW ANTIFUNGAL COMPOSITIONS|

---

DE102017119863A1|2017-08-30|2019-02-28|Jürgen Lademann|Cosmetic light and sunscreen|

---

BR112020012426A2|2017-12-19|2020-11-24|Dsm Ip Assets B.V.|topical composition|

---

JP2021506840A|2017-12-19|2021-02-22|ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ．|Local composition|

---

WO2019121466A1|2017-12-19|2019-06-27|Dsm Ip Assets B.V.|Topical composition|

---

WO2019192693A1|2018-04-05|2019-10-10|Beiersdorf Ag|Cosmetic composition for wet skin|

---

WO2019192694A1|2018-04-05|2019-10-10|Beiersdorf Ag|Anti-pollution shield|

---

KR102107295B1|2018-05-08|2020-05-07|선진뷰티사이언스|A photolite and making method for it|

---

JP2021523199A|2018-05-18|2021-09-02|ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ．|Local composition|

---

JP2021524848A|2018-05-18|2021-09-16|ディーエスエム アイピー アセッツ ビー．ブイ．Ｄｓｍ Ｉｐ Ａｓｓｅｔｓ Ｂ．Ｖ．|Local composition|

---

CN108635241A|2018-06-07|2018-10-12|上海蔻沣生物科技有限公司|One kind having thixotropic oiliness slurry and preparation method thereof|

---

US10660866B2|2018-09-10|2020-05-26|Johnson & Johnson Consumer Inc.|Retinol oil composition|

---

RU2721411C2|2018-10-05|2020-05-19|Общество с ограниченной ответственностью "ЮНИКОСМЕТИК"|Composition of lipophilic and hydrophilic sorbents for cleaning keratin fibres|

---

FR3090337B1|2018-12-21|2021-10-29|Oreal|FLUID PHOTOPROTECTOR COMPOSITION|

---

FR3091174B1|2018-12-26|2021-04-23|Oreal|Cosmetic composition comprising water-soluble UV filters|

---

CN113631141A|2019-03-01|2021-11-09|瓦塞尔曼梅迪奇公司|Novel compositions and uses thereof|

法律状态:
2016-03-29| B03A| Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]|

---

2018-02-27| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|

---

2019-08-13| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|

---

2020-07-14| B07A| Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]|

---

2020-11-17| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|

---

2021-01-26| B16A| Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2015, OBSERVADAS AS CONDICOES LEGAIS. |

优先权:

---

申请号 | 申请日 | 专利标题

---

EP14160519.6|2014-03-18|

---

EP14160519.6A|EP2921157B1|2014-03-18|2014-03-18|Coated titanium dioxide to reduce whitening effect on skin|

---